Patent Grant
8350055
The role of vasopressin in various pathological states has been the subject of intensive research in recent years, and the selective antagonism of the various vasopressin receptors opens up novel clinical prospects. At present, three receptors (V1a, V1b or V3 and V2) by which vasopressin mediates its effect are known. In contrast to the other two receptors, the vasopressin V1b receptor is mainly found in the CNS. This suggests that in particular CNS effects of vasopressin are mediated by the V1b receptor. Thus, it has also been, found that an antagonist of the V1b receptor shows anxiolytic and antidepressant effects (Griebel et al., PNAS 99, 6370 (2002); Serradeil-Le Gal et al., J. Pharm. Exp. Ther. 300, 1122 (2002)). Since the models used allow a certain forecast of a clinical effect, antagonists of the vasopressin V1b receptor might be useful for the treatment of emotional disturbances, e.g., stress, anxiety and depression.
WO 93/15051 and WO 98/25901 have already described 1-phenylsulfonyl-1,3-dihydro-2H-indol-2-ones in which the oxindole framework is substituted in position 3 by two alkyl radicals, which may also be a cycloalkyl radical (spiro linkage), as ligands of vasopressin receptors. An alternative possibility is for the spiro ring to contain heteroatoms such as oxygen and nitrogen (optionally with substituents).
WO 95/18105 describes 1-phenylsulfonyl-1,3-dihydro-2H-indol-2-ones which have a nitrogen atom in position 3 as ligands of vasopressin receptors. Additionally bonded in position 3 are radicals which may be alkyl, cycloalkyl, phenyl or benzyl radicals (optionally with substituents in each case).
Other publications describe compounds which have nitrogen-containing rings (e.g., proline, homoproline, morpholine, tetrahydroisoquinoline, dihydroindole; optionally with substituents in each case) bonded via their nitrogen atom to position 3 of the oxindole framework, but which have phenylsulfonyl or phenyl radicals (optionally with substituents) both in position 1 and position 3 on the oxindole ring.
The object of the present invention is to provide additional compounds for the treatment or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases which have high activity.
The object has been achieved by a compound of the formula (I)
in which
A is an aromatic heteromonocyclic, or an aromatic or partially aromatic heterobicyclic ring,
Ring A is preferably selected from the group consisting of aromatic heteromonocyclic and aromatic heterobicyclic systems comprising 1 or 2 heteroatoms, where one of the 2 heteroatoms is nitrogen, more preferably from benzothiazole, pyrimidine, pyridine, pyridazine, pyrazine, isoquinoline, quinoline, thiazole, benzimidazole, imidazole, benzoxazole, benzothiophene, thiophene, benzofuran and furan.
In a more preferred embodiment ring A is selected from the group consisting of pyridine, pyrimidine, pyrazine, thiophene, benzofuran and benzothiazole.
In a further preferred embodiment of the compound of formula (I), R11 and R12 are selected independently of one another from the group consisting of fluorine, chlorine, OH, O—C1-C4-alkyl and C1-C4-alkyl. More preferably, R11 and/or R12 are independently of one another methyl, methoxy or ethoxy.
Examples of ring A, substituted by R11 and/or R12, in the compound of formula (I) are 2-methoxypyridine-3-yl, 2-ethoxypyridine-3-yl, 2-hydroxypyridine-3-yl, 2,4-dimethoxypyrimidine-5-yl, 2,6-dimethoxypyridine-3-yl, 3-methoxypyridine-2-yl, 3-methoxypyridine-4-yl, 4-methoxypyridine-3-yl, 3-methoxypyrazine-2-yl, 3-methylthiophen-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl or 6-chlor-2-methoxypyridin-3-yl, preferably 2-methoxypyridine-3-yl, 2-ethoxypyridine-3-yl, 2,4-dimethoxy-pyrimidine-5-yl or 2,6-dimethoxypyridine-3-yl, and more preferably 2-methoxypyridine-3-yl.
In case of R11 or R12 being OH, the resultant substituted ring A may predominantly be present in form of its tautomer like, for example, 1,2-dihydro-2-oxopyridine-3-yl.
In a further preferred embodiment of the compounds of formulae (I) R6 and R7 are independently of one another hydrogen, fluorine, chlorine, bromine, iodine, C1-C4-alkyl, O—C1-C4-alkyl, CN, CF3 or OCF3, preferably hydrogen, fluorine, chlorine, methyl, methoxy, ethoxy or CN.
Furthermore, for the compounds of formula (I) R6 is preferably hydrogen, methoxy, methyl, F, CI or CN and/or R7 is preferably hydrogen, methoxy, methyl, F or CI.
The present application additionally relates to a compound of the formula (II)
in which
B is selected from the group consisting of thiophene, furan, pyrrole, pyridine, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, benzothiophene, benzofuran, dihydrobenzofuran, indole, dihydroisoindol,
an aromatic heteromonocyclic and an aromatic or partially aromatic heterobicyclic ring,
R5 is a radical (W)—(X)—(Y)—Z, where
X is selected from the group consisting of CO, CO—O, SO2, NR54, NR54—CO, NR54—SO2, CO—NR58 and a bond,
Ring B is preferably selected from the group consisting of thiophene, furan, pyrrole, pyrazole, isoxazole, pyridine, pyrimidine, quinoline, isoquinoline, tetrahydroisoquinoline, benzothiophene, benzofuran, indole, imidazole, thiazole, imidazothiazole, benzooxazine and quinoxaline.
In a more preferred embodiment ring B is selected from the group consisting of pyridine, imidazole, thiophene, benzothiophene and quinoline.
Even more preferably, ring B is selected from
In a further preferred embodiment of the compound of formula (II), R21 and R22 are selected independently of one another from the group consisting of hydrogen, chlorine, bromine, C1-C4-alkyl and O—C1-C4-alkyl. Particularly, R21 and R22 are independently of one another hydrogen, chlorine, bromine, methyl or methoxy.
In further particularly preferred embodiments, B is
wherein
In a further preferred embodiment of the compounds of formula (II) R6 and R7 are independently of one another hydrogen, fluorine, chlorine, bromine, iodine, C1-C4-alkyl, O—C1-C4-alkyl, CF3 or OCF3, preferably hydrogen, fluorine, chlorine, methyl, ethyl, propyl, i-propyl, methoxy, ethoxy, propoxy, i-propoxy.
For the compounds of formula (II) R6 is preferably hydrogen, methoxy, ethoxy, propoxy, i-propoxy, methyl, ethyl, fluorine or chlorine, most preferably methoxy or ethoxy. Further, R6 is more preferably in position 2 of the phenyl ring.
For the compounds of formula (II), R7 is preferably hydrogen, methoxy, F or CI, most preferably hydrogen.
The present invention additionally relates to a compound of the formula (III),
in which
D is an aromatic heteromonocyclic, or an aromatic or partially aromatic heterobicyclic ring,
Ring D is preferably selected from the group consisting of aromatic heteromonocyclic and aromatic heterobicyclic systems comprising 1 or 2 heteroatoms, where one of the 2 heteroatoms is nitrogen, more preferably from benzothiazole, pyrimidine, pyridine, pyridazine, pyrazine, isoquinoline, quinoline, thiazole, benzimidazole, imidazole, benzoxazole, benzothiophene, thiophene, benzofuran and furan.
In a particularly preferred embodiment ring ID is selected from the group consisting of pyridine, pyrimidine, pyrazine, thiophene, benzofuran and benzothiazole.
In a further preferred embodiment of the compound of formula (III) R21 and R22 are selected independently of one another from the group consisting of hydroxy, fluorine, chlorine, C1-C4-alkyl and O—C1-C4-alkyl. Particularly, R21 and R22 are independently of one another hydrogen, hydroxy, chlorine, methyl, methoxy or ethoxy, most preferably hydrogen, methyl, methoxy or ethoxy.
Examples of ring D, substituted by R21 and/or R22, are 2-methoxypyridine-3-yl, 2-ethoxypyridine-3-yl, 2-hydroxypyridine-3-yl, 2,4-dimethoxypyrimidine-5-yl, 2,6-dimethoxypyridine-3-yl, 3-methoxypyridine-2-yl, 3-methoxypyridine-4-yl, 4-methoxypyridine-3-yl, 3-methoxypyrazine-2-yl, 3-methylthiophen-2-yl, 3-methylpyridin-2-yl, pyridin-2-yl or 6-chlor-2-methoxypyridin-3-yl, preferably 2-methoxypyridine-3-yl, 2-ethoxypyridine-3-yl; 2; 4-dimethoxy-pyrimidine-5-yl or -2,6-dimethoxypyridine-3-yl, and more preferably 2-methoxypyridine-3-yl.
In case of R21 or R22 being OH, the resultant substituted ring D may predominantly be present in form of its tautomer like, for example, 1,2-dihydro-2-oxopyridine-3-yl.
Ring G is preferably selected from the group consisting of thiophene, furan, pyrrole, pyrazole, isoxazole, pyridine, pyrimidine, quinoline, isoquinoline, tetrahydroisoquinoline, benzothiophene, benzofuran, indole, imidazole, thiazole, imidazothiazole, benzooxazine and quinoxaline.
In a particularly preferred embodiment ring G is selected from the group consisting of imidazole, pyridine, thiophene, benzothiophene and quinoline.
Even more preferably, ring G is selected from
In a further preferred embodiment R71 and R72 are selected independently of one another from the group consisting of C1-C4-alkyl, O—C1-C4-alkyl, chlorine and bromine. Particularly, R71 and R72 are independently of one another methyl, methoxy, chlorine or bromine.
In a further particularly preferred embodiment ring G is
In preferred embodiments of the compounds of formulae (I), (II) or (III), R3 is selected from the group consisting of hydrogen, C1-4-alkyl, C2-4-alkenyl, C2-4-alkynyl, O—C1-4-alkyl, fluorine, chlorine, bromine, iodine, CN, CF3 and OCF3. More preferably, R3 is selected from the group consisting of methyl, methoxy, fluorine, chlorine, bromine, iodine, CN and OCF3.
Furthermore, in the compounds of formulae (I), (II) or (III) R3 is preferably present in position 5 of the oxindole ring:
R4 is in the compounds of formulae (I), (II) or (III) preferably hydrogen.
According to this preferred embodiment, R5 is a radical (W)—(X)—(Y)—Z as defined in the compounds of formulae (I), (II) or (III) wherein at least one, preferably two, more preferably three and particularly all of W, X, Y and Z have the following definition:
A preferred combination of W, X, Y and Z results in a group R5 having the following definition:
Preferably one, more preferably two and most preferably all of R51, R52 and R54 have the following definition:
In a further preferred embodiment E is azetidine, piperazine, pyrrolidine, piperidine or morpholine.
Furthermore, particularly preferred are combinations of preferred embodiments of the above defined groups in the first preferred embodiment of R5.
According to this preferred embodiment, R5 is a radical (W)—(X)—(Y)—Z as defined in the compounds of formulae (I), (II) or (III) wherein at least one, preferably two, more preferably three and particularly all of W, X, Y and Z have the following definition:
Preferably, E is a saturated or partially unsaturated monocyclic ring having a maximum of 8, preferably a maximum of 6 and particularly 4 or 5 carbon atoms, and 0 to 3, preferably 1 or 2 and particularly 1 nitrogen atom.
In a further preferred embodiment E is azetidine, piperazine, pyrrolidine or piperidine.
In a further preferred embodiment E is piperidine bonded to Z via the ring nitrogen atom.
In one preferred embodiment E is unsubstituted.
In another preferred embodiment E is substituted by one or two radicals R53, with R53 being defined as in the compounds of formulae (I), (II) or (III). More preferably R53 is fluorine, OH, C1-C4-alkyl, O—C1-C4-alkyl or CN, more preferably fluorine, OH, methyl or methoxy and most preferably fluorine or OH. In a further preferred embodiment E is substituted by two radicals R53 in geminal position, particularly with R53 being fluorine.
In a further preferred embodiment E is substituted by one radical R55 as defined in the compounds of formulae (I), (II) or (III). More preferably R55 is phenyl, O-phenyl or O-benzyl.
Furthermore, E is preferably substituted by one radical R56 as defined in the compounds of formulae (I), (II) or (III) wherein at least one, preferably two and particularly all of Q1, Q2 and Q3 have the following definition:
In a further preferred embodiment Q3 is azetidine, piperazine, pyrrolidine, piperidine or morpholine.
Moreover, E is preferably substituted by one radical R57 as defined in the compounds of formulae (I), (II) or (III). More preferably R57 is CO—N(C1-C4-alky)2 or CO—O—C1-C4-alkyl, and in particular CO—N(CH3)2.
Preferred combinations of W, X, Y, Z, R53, R55 and/or R57 result in groups R5 having the following definition:
wherein
More preferred combinations of W, X, Y, Z, R53 and/or R57 result in groups R5 having the following definition:
Particularly preferred combinations of W, X, Y, Z, R53 and/or R57 result in groups R5 having the following definition:
Furthermore, particularly preferred are combinations of preferred embodiments of the above defined groups in the second preferred embodiment of R5.
In a further preferred embodiment a compound of the formula (I), (II) or (III) is disclosed, wherein E is pyrrolidine bonded to Z via the ring nitrogen atom, with R53 at position C-4 and selected from the group consisting of fluorine, OH, C1-C4-alkyl, O—C1-C4-alkyl or CN, and with R56 at position C-2 selected from the group consisting of hydrogen, C1-C4-alkyl, phenyl, C1-C4-alkylen-phenyl, COOH, CO—O—C1-C4-alkyl, CONH2, CO—NH—C1-C4-alkyl, CO—N(C1-C4-alkyl)2, CO—C1-C4-alkyl, CH2—NH2, CH2—NH—C1-C4-alkyl and CH2—N(C1-C4-alkyl)2.
According to this preferred embodiment, R5 is a radical (W)—(X)—(Y)—Z as defined in the compounds of formulae (I), (II) or (III) wherein at least one, preferably two, more preferably three and particularly all of W, X, Y and Z have the following definition:
Preferably, E is a saturated or partially unsaturated monocyclic ring having a maximum of 8, preferably a maximum of 6 and particularly 4 or 5 carbon atoms, and 0 to 3, preferably 1 or 2 nitrogen atoms.
More preferably E is selected from the group consisting of
even more preferably from the group consisting of
and most preferably E is
wherein one bond ‘—*’ defines the bonding position to group Y and the second bond ‘—*’ defines the bonding position to an optional substituent R56.
Further, according to one embodiment E is
Moreover, according to another embodiment E is
Preferably, E is substituted by R56 as defined in compounds of formulae (I), (II) or (III), wherein at least one, preferably two and particularly all of Q1, Q2 and Q3 have the following definition:
Preferably, Q3 is substituted by R63 as defined in compounds of formulae (I), (II) or (III). R63 is preferably C1-C4-alkyl and particularly methyl.
More preferably, Q3 is selected from the group consisting of
and even more preferably from the group consisting of
Still more preferably Q3 is
According to one embodiment Q3 is
According to another embodiment Q3 is
Particularly preferred are combinations of W, X, Y, Z and R63 resulting in the following groups R5:
Furthermore, particularly preferred are combinations of preferred embodiments of the above defined groups in the third preferred embodiment of R5.
Particularly preferred are compounds of formula (I) wherein at least two and most preferably all of A, R3, R4, R5, R6 and R7 are defined according to above described preferred embodiments of these groups.
Particularly preferred are further compounds of formula (II) wherein at least two and most preferably all of B, R3, R4, R5, R6 and R7 are defined according to above described preferred embodiments of these groups.
Particularly preferred are moreover compounds of formula (III) wherein at least two and most preferably all of A, R3, R4, R5, R6 and R7 are defined according to above described preferred embodiments of these groups.
The terms “alkyl”, “alkylene”, “alkenyl”, “alkenylene”, “alkynyl” and “alkynylene” as used herein always include unbranched or branched “alkyl”, “alkylene”, “alkenyl”, “alkenylene”, “alkynyl” or “alkynylene”.
C1-C4-alkyl as used herein is preferably methyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl or t-butyl.
C1-C4-alkylene as used herein is preferably methylene, ethylene, or branched or unbranched propylene or butylene.
C2-C4-alkenyl as used herein is preferably ethenyl, or branched or unbranched propenyl or butenyl.
C2-C4-alkenylene as used herein is preferably ethenylene, or branched or unbranched propenylene or butenylene.
C2-C4-alkynyl as used herein is preferably ethynyl, or branched or unbranched propynyl or butynyl.
C2-C4-alkynylene as used herein is preferably ethynylene, or branched or unbranched propynylene or butynylene.
C1-C6-alkyl as used herein is preferably branched or unbranched hexyl or pentyl, more preferably C1-C4-alkyl, and in particular methyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl or t-butyl.
C1-C6-alkylene as used herein is preferably branched or unbranched hexylene or pentylene, more preferably C1-C4-alkylene, and in particular methylene, ethylene, or branched or unbranched propylene or butylene.
C2-C6-alkenyl as used herein is preferably branched or unbranched hexenyl or pentenyl, more preferably C2-C4-alkenyl, and in particular ethenyl, or branched or unbranched propenyl or butenyl.
C2-C6-alkenylene as used herein is preferably branched or unbranched hexenylene or pentenylene, more preferably C2-C4-alkenylene, and in particular ethenylene, or branched or unbranched propenylene or butenylene.
C2-C6-alkynyl as used herein is preferably branched or unbranched hexynyl or pentynyl, more preferably C2-C4-alkynyl, and in particular ethynyl, or branched or unbranched propynyl or butynyl.
C2-C6-alkynylene as used herein is preferably branched or unbranched hexynylene or pentynylene, more preferably C2-C4-alkynylene, and in particular ethynylene, or branched or unbranched propynylene or butynylene.
As used herein, “benzothiazole” means 2-, 3-, 4-, 5-, 6- or 7-benzothiazole, “pyrimidine” means 2-, 4-, 5-, or 6-pyrimidine, “pyridine” means 2-, 3-, 4-, 5- or 6-pyridine, “pyridazine” means 3-, 4-, 5- or 6-pyridazine, “pyrazine” means 2-, 3-, 5- or 6-pyrazine, “isoquinoline” means 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinoline, “quinoline” means 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinoline, “thiazole” means 2-, 4- or 5-thiazole, “benzimidazole” means 2-, 4-, 5-, 6- or 7-benzimidazole, “imidazole” means 2-, 4- or 5-imidazole, “benzoxazole” means 2-, 4-, 5-, 6- or 7-benzoxazole, “benzothiophene” means 2-, 3-, 4-, 5-, 6-, or 7-benzothiophene, “thiophene” means 2-, 3-, 4- or 5-thiophene, “benzofuran” means 2-, 3-, 4-, 5-, 6- or 7-benzofuran and “furan” means 2-, 3-, 4- or 5-furan.
Further, as used herein, “pyrrole” means 2-, 3-, 4- or 5-pyrrole, “tetrahydroquinoline” means 1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-tetrahydroquinoline, “tetrahydroisoquinoline” means 1-, 2-, 3-, 4-, 5-, 6-, 7- or 8-tetrahydroisoquinoline, “dihydrobenzofuran” means 2-, 3-, 4-, 5-, 6- or 7-dihydrobenzofuran, “indole” means 1-, 2-, 3-, 4-, 5-, 6- or 7-indole, “dihydroisoindole” means 1-, 2-, 3-, 4-, 5-, 6- or 7-dihydroisoindole.
Further, as used herein, “pyrazole” means 1-, 3-, 4- or 5-pyrazole, “isoxazole” means 3-, 4- or 5-isoxazole, “imidazothiazole” means 2-, 4-, 5- or 6-imidazothiazole, “benzoxazine” means 2-, 3-, 4-, 5-, 6-, 7- or 8-benzoxazine, “quinoxaline” means 2-, 3-, 5-, 6-, 7- or 8-quinoxaline.
Further, as used herein, “azetidine” means 1-, 2-, 3- or 4-azetidine, “piperazine” means 1-, 2-, 3-, 4-, 5- or 6-piperazine, “pyrrolidine” means 1-, 2-, 3-, 4- or 5-pyrrolidine, “piperidine” means 1-, 2-, 3-, 4-, 5- or 6-piperidine and “morpholine” means 2-, 3-, 4-, 5- or 6-morpholine.
At each occurrence in the present application, the formulations “NR54” and CO—NR58 shall, particularly in a preferred embodiment, include NHR54 and CO—NHR58, respectively.
At each occurrence in the present application, the formulation “N(definition of residue)number” (e.g., “N(C1-C4-alkyl)2”) shall, particularly in a preferred embodiment, be understood that each of the residues according to the given “number” may have independently of each other either the same or different meanings. For example, “N(C1-C4-alkyl)2” shall represent “N(C1-C4-alkyl)(C1-C4-alkyl)” wherein both residues “(C1-C4-alkyl)” are each bonded to the nitrogen atom and may have either the same or different meanings.
At each occurrence in the present application, the formulation “E is an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms and/or 0 to 2 sulfur atoms, said ring may comprise up to two oxo groups, and may be substituted by radicals R55, R56, R57, and/or up to three radicals R53” shall, particularly as a preferred embodiment, have the meaning of “E is an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring having as ring members any of from 2 to (a maximum of) 14 carbon atoms and any of 0, 1, 2, 3, 4 and 5 nitrogen atoms, any of 0, 1 and 2 oxygen atoms and any of 0, 1 and 2 sulfur atoms, said ring comprising any of 0, 1 and 2 oxo groups and be optionally substituted at the ring carbon atom and/or ring nitrogen atom by from one to three radicals selected from the group consisting of R55, R56 and R57, and with 1, 2 or 3 radicals R53 which independently of each other may have either identical or different meanings, wherein E can be bonded to Y via a carbon ring atom or a nitrogen ring atom” and, more preferably, the meaning of “E is an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring having as ring members 2, 3, 4; 5, 6, 7, 8, 9, 10, 11, 12, 13 or a maximum of 14 carbon atoms and 0, 1, 2, 3, 4 or 5 nitrogen atoms, 0, 1 or 2 oxygen atoms and/or 0, 1 or 2 sulfur atoms, said ring comprise 0, 1 or 2 oxo groups and be optionally substituted at the ring carbon atom and/or ring nitrogen atom by radicals R55, R56 and/or R57, and/or with 1, 2 or 3 radicals R53 which independently of each other may have either identical or different meanings, wherein E can be bonded to Y via a carbon ring atom or a nitrogen ring atom”.
At each occurrence in the present application, the formulation “Q3 is a hydrogen or an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring having as ring members a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms and/or 0 to 2 sulfur atoms, which may comprise up to two oxo groups and may be substituted by the radicals R63, R64 and/or R65” shall have, particularly as a preferred embodiment, the meaning of “Q3 is a hydrogen or an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring having as ring members any from 2 to (a maximum of) 14 carbon atoms and any of 0, 1, 2, 3, 4 and 5 nitrogen atoms, and any of 0, 1 and 2 oxygen atoms and any of 0, 1 and 2 sulfur atoms, said ring may comprise any of 0, 1 and 2 oxo groups and may be substituted at the carbon ring atom and/or the nitrogen ring atom by the radicals R63, R64 and/or R65 which independently of each other may have either identical or different meanings, wherein Q3 can be bonded to Q2 via a Carbon ring atom or a nitrogen ring atom” and, more preferably, the meaning of “Q3 is a hydrogen or an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring having as ring members any of from 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14 carbon atoms and any of 0, 1, 2, 3, 4 and 5 nitrogen atoms, and any of 0, 1 and 2 oxygen atoms and any of 0, 1 and 2 sulfur atoms, said ring may comprise any of 0, 1 and 2 oxo groups and may be substituted at the carbon ring atom and/or nitrogen ring atom by the radicals R63, R64 and/or R65 which independently of each other may have either identical or different meanings, wherein Q3 can be bonded to Q2 via a carbon ring atom or a nitrogen ring atom”.
At each occurrence in the present application, the formulation “where the heterocycles are 5- or 6-membered rings and comprise up to 4 heteroatoms selected from the group consisting of N, O and S, and up to 2 oxo groups, where not more than one of the heteroatoms is an oxygen atom” shall have, particularly as a preferred embodiment, the meaning of “where the heterocycles as forming part of the heteromonocyclic or heterobicyclic ring are 5- or 6-membered rings and per heteromonocyclic or heterobicyclic ring may comprise any of 1, 2, 3 and 4 heteroatoms which independently of each other are selected from the group consisting of N, O and S, said heterocycles may further comprise any of 0, 1 and 2 oxo groups, whereby not more than one of the heteroatoms is an oxygen atom”.
At each occurrence in the present application, the formulation “where the heterocycles are 5- or 6-membered rings and comprise 2 to 4 heteroatoms selected from the group consisting of N, O and S, and up to 2 oxo groups” shall have, particularly as a preferred embodiment, the meaning of “where the heterocycles as forming part of the heteromonocyclic or heterobicyclic ring are 5- or 6-membered rings and per heteromonocyclic or heterobicyclic ring may comprise any of 2, 3 and 4 heteroatoms which independently of each other are selected from the group consisting of N, O and S, said heterocycles may further comprise any of 0, 1 and 2 oxo groups”.
At each occurrence in the present application, the formulation “where the heterocycles are 5- or 6-membered rings and comprise up to 4 heteroatoms selected from the group consisting of N, O and S, and up to 2 oxo groups” shall have, particularly as a preferred embodiment, the meaning of “where the heterocycles as forming part of the heteromonocyclic or heterobicyclic ring are 5- or 6-membered rings and per heteromonocyclic or heterobicyclic ring may comprise any of 1, 2, 3 and 4 heteroatoms which independently of each other are selected from the group consisting of N, O and S, said heterocycles may further comprise any of 0, 1 and 2 oxo groups”.
At each occurrence in the present application, in a preferred embodiment the residue R3 is placed at position C-5 of the 1,3-dihydroindol-2-one and selected from the group consisting of hydrogen, chlorine, bromine, iodine, fluorine, CN, CF3, OCF3, NO2, OH, O—C1-C4-alkyl, O-phenyl, O—C1-C4-alkylen-phenyl, phenyl, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, NH2, NH(C1-C4-alkyl) and N(C1-C4-alkyl)2 and R4 is hydrogen.
The formulation “partially aromatic” as used herein means an aromatic system comprising two or more double bonds wherein at least one of said double bonds has been hydrogenated by addition of hydrogen, whereby the remaining one or more double bounds may be either standing alone (in case of one double bound only), conjugated, partially conjugated or no longer conjugated with each other.
The formulation the “[said] ring may comprise up to two oxo groups” as used herein means that said ring has up to two carbon atoms which are each connected to an oxygen atom via a double bond.
Divalent radicals are to be read from the left to the right with respect to their bonds to other substructures of the molecule. Thus, for example “CO—NR58” in the definition of X in R5 of the compound of formulae (I) to (IIII) is connected to W and Y as follows: (W)—CO—N(R58)—(Y)—Z.
By prodrugs are meant those compounds which are metabolized in vivo to the compounds of the invention. Typical examples of prodrugs are described in C. G. Wermuth (ed.): The Practice of Medicinal Chemistry, Academic Press, San Diego, 1996, pp. 671-715. These include, for example, phosphates, carbamates or amino acids, esters and others.
The invention further relates to the physiologically tolerated salts of the compounds of the invention which can be obtained by reacting the compounds of the invention with a suitable acid or base. Suitable acids and bases are listed for example in Fortschritte der Arzneimittelforschung, 1966, Birkhäuser Verlag. vol. 10, pages 224-285. These include for example hydrochloric acid, citric acid, tartaric acid, lactic acid, phosphoric acid, methanesulfonic acid, acetic acid, formic acid, maleic acid, fumaric acid etc., and sodium hydroxide, lithium hydroxide, potassium hydroxide and 2-amino-2-(hydroxymethyl)-1,3-propanediol (Tris).
The invention further relates to the compound of any of general formulae (I) to (III) as therapeutic or prophylactic agent.
Furthermore, the invention relates to a medicament comprising the compound of any of general formulae (I) to (III).
The compound of any of general formulae (I) to (III) can be used for producing a medicament for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases.
The invention further relates to the use of the compound of any of general formulae (I) to (III) for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases.
A further aspect of the invention is a method for the therapeutic and/or prophylactic treatment of a mammal requiring a treatment by administering the compound of any of formulae (I) to (III) for the treatment of diseases.
Furthermore, the compound of any of formulae (I) to (III) can be used for the treatment of:
depressions and/or bipolar disorders such as, for example, dysthymic disorders, subsyndromal depression, seasonal affected disorders, premenstrual dysphoric disorders and/or psychotic disorders;
anxiety and/or stress-related disorders such as, for example, general anxiety disorders, panic disorders, obsessive-compulsive disorders, post-traumatic disorders, acute stress disorders and/or social phobia;
memory disorders and/or Alzheimer's disease;
psychoses and/or psychotic disorders; and/or
Cushing's syndrome.
The compounds of the invention are effective after administration in various ways, especially orally.
The compounds according to the present invention can be useful for the treatment or prevention of various vasopressin-dependent or ocytocin-dependent complaints, such as mental disorders. Examples of such mental disorders according to the American Psychiatric Association DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th ed., 1994 are attention-deficit and disruptive behavior disorders; delirium, dementia, and amnestic and other cognitive disorders; substance-related disorders, such as alcohol use disorders and alcohol-induced disorders; schizophrenia and other psychotic disorders, such as schizophrenia, schizophreniform disorder, schizoaffective disorder and delusional disorder; mood disorders; such as depressive disorders (major depressive disorder, dysthymic disorder, seasonal affective disorder, premenstrual dysphoric disorder, depressive disorder not otherwise specified), bipolar disorder (bipolar I disorder, bipolar II disorder, cyclothymic disorder, bipolar disorder not otherwise specified, substance-induced mood disorder, mood disorder not otherwise specified); stress-related disorders, such as acute stress disorder; anxiety disorders, such as panic disorder without agoraphobia, panic disorder with agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, obsessive-compulsive disorder, posttraumatic stress disorder, acute stress disorder, generalized anxiety disorder, substance-induced anxiety disorder; somatoform disorders, such as somatization disorder, undifferentiated somatoform disorder, conversion disorder, pain disorder; eating disorders; sleep disorders, such as primary sleep disorders (dyssomnias, parasomnias), sleep disorders related to another mental disorder. Furthermore, compounds according to the present invention can be useful for the treatment of Cushing syndrome.
The present invention also relates to pharmaceutical compositions which comprise an effective dose of a compound of the invention or of a pharmaceutically acceptable salt thereof and suitable pharmaceutical carriers.
These pharmaceutical carriers are chosen according to the pharmaceutical form and the desired mode of administration.
With the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, intratracheal, intranasal, transdermal or rectal administration it is possible to administer the compounds of the formula (I), (II) or (III) or, where suitable, the salts thereof to animals or humans in unitary administration forms, mixed with conventional pharmaceutical carriers, for the prophylaxis or treatment of the above disorders or diseases.
The suitable unitary administration forms include forms for oral administration, such as tablets, gelatin capsules, powders, granules and solutions or suspensions for oral intake, forms for sublingual, buccal, intratracheal or intranasal administration, aerosols, implants, forms for subcutaneous, intramuscular or intravenous administration and forms for rectal administration.
For topical administration, the compounds of the invention can be used in creams, ointments or lotions.
In order to achieve the desired prophylactic or therapeutic effect, the dose of the basic active ingredient may vary between 0.01 and 50 mg per kg of bodyweight and per day.
Each unit dose may comprise from 0.05 to 5 000 mg, preferably 1 to 1 000 mg, of the active ingredient in combination with a pharmaceutical carrier. This unit dose may be administered 1 to 5 times a day so that a daily dose of from 0.5 to 25 000 mg, preferably 1 to 5 000 mg, is administered.
If a solid composition is prepared in the form of tablets, the main ingredient is mixed with a pharmaceutical carrier such as gelatin, starch, lactose, magnesium stearate, talc, silica or the like.
The tablets may be coated with sucrose, a cellulose derivative or another suitable substance or treated otherwise in order to display persistent or delayed activity and in order to release a predetermined amount of the basic active ingredient continuously.
A preparation in the form of gelatin capsules is obtained by mixing the active ingredient with an extender and taking up the resulting mixture in soft or hard gelatin capsules.
A preparation in the form of a syrup or elixir or for administration in the form of drops may comprise active ingredients together with a sweetener, which is preferably calorie-free, methylparaben or propylparaben as antiseptics, a flavoring and a suitable color.
The water-dispersible powders or granules may comprise the active ingredients mixed with dispersants or wetting agents, or suspending agents, such as polyvinylpyrrolidones, and sweeteners or masking flavors.
Rectal administration is achieved by using suppositories which are prepared with binders which melt at the rectal temperature, for example cocoa butter or polyethylene glycols. Parenteral administration is effected by using aqueous suspensions, isotonic salt solutions or sterile and injectable solutions which comprise pharmacologically acceptable dispersants and/or wetting agents, for example propylene glycol or polyethylene glycol.
The basic active ingredient may also be formulated as microcapsules or liposomes, if suitable with one or more carriers or additives.
In addition to the compounds of the general formula (I) or their pharmaceutically acceptable salts, the compositions of the invention may comprise other basic active ingredients which may be beneficial for the treatment of the abovementioned disorders or diseases.
The present invention thus further relates to pharmaceutical compositions in which a plurality of basic active ingredients are present together, where one of these is the compound of the invention.
The compounds of the invention were tested for their activity in the following vasopressin V1b receptor binding assay.
Vasopressin V1b Receptor Binding Assay
The binding of the compounds of this invention to the vasopressin V1b receptor was determined with the following assay:
Dissolution of Compounds
Compounds were dissolved in a concentration of 10−2 M or 10−3 M in DMSO. Further dilutions were performed with water.
Binding Assays
The procedure for the binding assay was based on the method of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)). Assays (0.250 ml) consisted of membranes (58 μg protein) from CHO-K1 cells permanently expressing human V1b receptors (preparation V1b-3H2, containing protease inhibitors, Roche complete Mini #1836170), 1.5 nM 3H-AVP (8-Arg-vasopressin, NET 800) in incubation buffer (total binding) and different concentrations of test compound (displacement). Non-specific binding was defined with 10−6 M AVP. Assays were performed in triplicate.
Incubation buffer: 50 mM Tris, 10 mM MgCl2, 0.1% BSA adjusted to pH 7.4 with HCl.
After incubation, 60 min at room temperature, bound and free radioligand was separated by filtration under vacuum through Whatman GF/B glass fibre mats using a Skatron cell harvester 7000.
Liquid scintillation counting was performed in beta-counters, Tricarb model 2000 or 2200CA (Packard). Dpm were calculated by a programme with standardisation using a standard quench series.
Evaluation
Evaluation of binding parameters was performed by non-linear regression analysis with SAS. The strategy of this program is similar to the program LIGAND described by Munson and Rodbard (Munson P J and Rodbard D, Analytical Biochem 107, 220-239 (1980)).
The compounds of the invention bind to the vasopressin V1b receptor. In the following Table 1 the binding affinity of selected examples for the vasopressin V1b receptor is shown.
Functional Assay for the Human V1b Receptor
Functional activity was determined by testing the effect of the compounds on calcium release in CHO-K1 cells stably transfected with human V1b) receptor. Cells were seeded into 96-well plates at 50,000 cells/well and grown overnight in tissue culture medium (DMEM/Nut mix F12 Medium with Glutamax I (Invitrogen), containing 10% FCS, 100 units/ml Penicillin, 100 μg/ml Streptomycine, 800 μg/ml Geneticin) at 37° C. and 5% CO2. Cells were loaded with a fluorescent calcium-sensitive dye in the presence of 1% probenicid according to the manufacturers protocol (Ca++-Plus-Assay Kit, Molecular Devices). Serial compound dilutions (final concentrations 10−10 to 10−5 M) were added to the cells either alone or in the presence of Arg-vasopressin (10−8M) and the maximum calcium response was determined using a FLIPR-96 instrument (Molecular Devices). Concentration-response curves were fitted using a three-parameter logistic equation (GraphPad Prism). Kb values were calculated from IC50 values according to Cheng & Prusoff (Kb=IC50/(1+L/EC50)).
Antidepressant Effects of Compounds of this Invention in the Rat Forced Swim Model
The potential antidepressant effects of some examples of this invention were examined in the rat forced swim test. When rats are forced to swim in a cylinder from which no escape is possible they readily adopt a characteristic immobile posture and make no further attempts to escape except for small movements needed to keep floating. The immobility is considered to reflect a ‘depressive mood’ (Porsolt R D, LePichon M, Jalfre M (1977). Depression: a new animal model sensitive to antidepressant treatment. Nature 266, 730-732), in which animals cease to struggle to escape the aversive situation. The immobility induced by the procedure is influenced by a wide variety of antidepressants (Porsolt R D, Lenegre A, McArthur R A (1991). Pharmacological models of depression. In: Animal models in Psychopharmacology. B. Olivier, J. Mos, J. L. Slangen (eds) Birkhauser Verlag, Basel, pp. 137-159) and has a good predictive validity in that it detects antidepressants with different mechanisms of action. Administration of antidepressants such as fluoxetine increases the time an animal struggles (decreases the immobility time) when forced to swim in a confined space. Lack of struggling is thought to represent a state of despair.
Procedure: Male Sprague Dawley rats (Janvier) weighing 160-200 gram (n=6) were placed individually into a glass water tank (40 cm×21.5 cm) filled with tap water (25° C.) up to 18 cm. This pre-test lasted for 15 min. Twenty-four hours later, animals were re-tested for 5 min in the same water tank while the total immobility time, swimming time and climbing time were recorded. Rats were considered immobile when they made no further attempts to escape, except for movements necessary to keep their heads above water (Porsolt R D, Anton G, Blavet N & Jalfre M. (1978). Behavioral despair in rats: a new model sensitive to antidepressant treatments. European Journal of Pharmacology 47, 379-391). The absence of hind limb movements was recorded as immobility using a stopwatch by a single observer. The water in the bath was changed after each trial. Drugs were administered via intraperitoneal route as suspensions in hydroxypropylmethylcellulose (HPMC) three times before re-testing (for example 24, 4 and 0.5 hours before re-testing, depending on the test compound).
Some of the compounds of the invention, when tested in the rat forced swim model, yielded results strongly suggestive of antidepressant activity. The compounds of Examples 5 and 29 decreased the immobility time in a dose-dependent manner with an ED50 of <30 mg/kg. In comparison, SSR149415 (Griebel et al., PNAS 99, 6370 (2002)), an antidepressant-like compound that is structurally related to some compounds of this invention, showed an ED50 value of >30 mg/kg in our rat forced swim model.
These data show that subtle changes, such as replacing the 2-methoxy-phenyl group in SSR149415 with a 2-methoxy-pyridin-3-yl group or replacing the 2,4-dimethoxy-benzenesulfonyl moiety with a thiophene-2-sulfonyl moiety, can lead to compounds having significantly enhanced activity in the rat forced swim model. Lower ED50 values, in turn, are likely to result in lower doses being required to obtain antidepressant effects, thus offering the possibility of an improved therapeutic index.
The synthesis of the compounds of the invention is described below.
The 1,3-dihydroindol-2-ones of the invention can be prepared in various ways, as outlined in synthesis Schemes 1-5.
The 3-hydroxy-1,3-dihydroindol-2-ones VI can be obtained by addition of metalated heterocycles IV to the 3-keto group of isatins V. Examples of metalated heterocycles which can be employed are the corresponding magnesium and lithium compounds. The isatins V were either purchased or prepared by methods described in the literature (Advances in Heterocyclic Chemistry, A. R. Katritzky and A. J. Boulton, Academic Press, New York, 1975, 18, 2-58; J. Brazil. Chem. Soc. 12, 273-324 (2001)). The metalated heterocycles IV were prepared in various ways (see review article by G. Queguiner et al. in Advances in Heterocyclic Chemistry, Vol. 52, ed. A. R. Katritzky, Academic Press, 1991, 187-304: J. Heterocyclic Chem. 37, 615 (2000); Heterocyles 37, 2149, (1994)): (i) reaction of heteroaryl halides with magnesium affords in certain cases (for example 2-bromo-3-methylthiophene) the corresponding Grignard compounds (M=Mg); (ii) reaction of heteroaryl bromides and iodides with alkyllithium reagents such as, for example, n-butyllithium, tert-butyllithium or mesityllithium at low temperatures affords in certain cases (for example 5-bromo-2,4-dimethoxypyrimidine) the lithiated heterocycles by halogen-lithium exchange; (iii) reaction of substituted heterocycles with the aforementioned alkyllithium reagents and lithium bases such as, for example, lithium diisopropylamide or lithium tetramethylpiperidylamide likewise affords in certain cases (for example 2-methoxypyrazine) the lithiated heterocycles, especially when the hetero-aromatic system is substituted by ortho-directing groups such as, for example, a methoxy group.
The 3-hydroxy-1,3-dihydroindol-2-ones VI were converted in the next step into compounds VII which bear a leaving group LG in position 3. Examples for LG are halides, mesylate and tosylate. Thus, for example, in the case where LG is chlorine the intermediate VII can be prepared by treating the tertiary alcohol VI with thionyl chloride in the presence of a base such as, for example, pyridine. Alternatively, alcohols VI can be activated by conversion into the mesylate using methanesulfonyl chloride in the presence of a base such as, for example, triethylamine. The leaving group LG in the compounds VII can then be replaced by various nucleophiles R5-H, resulting in the compounds VIII which have the radical R5 in position 3. For example, replacement reactions with primary and secondary amines R5-H in the presence of a base such as, for example, N,N-diisopropylethylamine in a solvent such as, for example dichloromethane afford the analogous 3-amino-1,3-dihydroindol-2-ones VIII. The reaction is not confined to nitrogen nucleophiles; it is also possible for oxygen or sulfur nucleophiles R5-H, where appropriate after deprotonation with a suitable base such as, for example, sodium hydride.
Final sulfonylation by treating the compounds VIII with the sulfonyl chlorides IX after deprotonation with a strong base such as, for example, potassium tert-butoxide or sodium hydride in a solvent such as, for example, DMF affords the compounds X of the invention.
The 3-urethane derivatives XIII were prepared by initially reacting the 3-hydroxy-1,3-dihydroindol-2-ones VI with heterocyclic sulfonyl chlorides XI under the conditions already described above. Heterocyclic sulfonyl chlorides were either purchased or prepared by standard methods (see, for example, J. Med. Chem. 40, 1149 (1997); J. March, Advanced Organic Chemistry, 1992, 4th ed., Wiley, New York, p. 724). The compounds XIII of the invention were prepared in various ways starting from the sulfonylated compounds XII: (i) reaction with isocyanates L=C═O (L contains nitrogen); (ii) reaction with carbamoyl chlorides L-CO—CI (L contains nitrogen) in the presence of a base such as, for example, triethylamine; (iii) activation with phenyl chloroformate in the presence of a base such as, for example, pyridine and subsequent reaction of the carbonate intermediate with amines L-H, where appropriate at elevated temperature. Heteroaryl-substituted piperidines, that can be employed as amines L-H, can be prepared as described in Tetrahedron Lett. 34, 5287 (1993) and Bioorg. Med. Chem. Lett. 11, 2213 (2001) for 4-(4′-piperidinyl)-pyridine.
Compounds XXII of the invention bearing a functionalized nitrogen atom in position 3 (e.g., amides, sulfonamides, carbamates and ureas) were prepared as described in synthesis Scheme 3. The 3-amino-1,3-dihydroindol-2-ones XX were prepared for example by reacting compounds VII (LG is a leaving group such as, for example, chloride or mesylate) with primary amines R54—NH2 in the presence of a base such as, for example, N,N-diisopropylethylamine in suitable solvents such as, for example, dichloromethane. Treatment of compounds XX with sulfonyl chlorides XI after deprotonation with a strong base such as, for example, potassium tert-butoxide or sodium hydride in a solvent such as, for example, DMF afforded the 3-amino-1,3-dihydroindol-2-ones XXI sulfonylated in position 1. The amino derivatives XXII of the invention were prepared from the amines XXI by reaction with customary reagents for derivatizing amino groups, such as, for example, carboxylic acids, carbonyl chlorides, carboxylic anhydrides, sulfonyl chlorides, chloroformates, isocyanates, carbamoyl chlorides by the relevant methods (J. March, Advanced Organic Chemistry, 1992, 4th ed., Wiley, New York, pp. 417-421; 499; 903).
N-heteroaryl-substituted piperidine carboxylic acids, that can be employed as coupling partner for the amines XXI, can be prepared for example as described in J. Med. Chem. 43, 2087 (2000) for 4-carboxy-N-(4-pyridyl)piperidine.
In addition, the 3-amino group in the compounds XXI can be substituted by treatment with alkylating agents such as, for example, alkyl bromides, iodides or mesylates, and by reaction with aldehydes or ketones in the presence of reducing agents such as, for example, sodium cyanoborohydride in the sense of a reductive amination (J. March, Advanced Organic Chemistry, 1992, 4th ed., Wiley, New York, p. 411; 898).
Compounds XXVII of the invention in which X—Y—Z radicals are linked via an alkylene bridge W to position 3 of the 1,3-dihydroindol-2-one framework were prepared for example by alkylation of the deoxygenated compounds XXIII and, where appropriate, derivatized further. An example for the preparation of compounds of the XXVII type in which W is a methylene group and X is a carbonyl group is described in synthesis Scheme 4: Deoxygenation of the 3-hydroxy-1,3-dihydroindol-2-ones VI took place with triethylsilane in trifluoroacetic acid. The esters XXIV were prepared by alkylation of the 1,3-dihydroindol-2-ones XXIII with ethyl bromoacetate in the presence of bases such as, for example, potassium carbonate and, where appropriate, potassium iodide. After hydrolysis of the ester function, for example by treatment with lithium hydroxide in a water/THF/methanol mixture, the acids XXV were coupled with amines H—Y—Z employing relevant methods (J. March, Advanced Organic Chemistry, 1992, 4th ed., Wiley, New York, pp. 417-421). Final sulfonylation of the compounds XXVI with sulfonyl chlorides XI afforded the compounds XXVII of the invention.
Compounds of the invention in which X—Y—Z radicals are linked via an oxygen atom (W═O) to position 3 of the 1,3-dihydroindol-2-one framework were prepared for example by alkylation of the 1-sulfonyl-3-hydroxy-1,3-dihydroindol-2-ones XII with alkylating agents such as, for example, aralkyl bromides, iodides or mesylates after deprotonation of the tertiary hydroxyl group with bases such as, for example, sodium hydride.
Enantiopure compounds can be obtained for example by carrying out a conventional racemic resolution using suitable optically active acids or bases with compounds of the invention or intermediates which comprise basic or acidic functional groups such as, for example, an amino or carboxyl group.
A) BOP (172 g, 0.389 mol) was added in portions to a solution of (2S,4R)-1-(tert-butoxycarbonyl)-4-hydroxy-pyrrolidine-2-carboxylic acid (90 g, 0.398 mol) in dichloromethane (450 ml) and DIPEA (68 ml, 0.523 mol) at 0° C. and stirred at 0° C. for 1 hour. Then a 2 M solution of dimethylamine in THF (800 ml, 1.6 mol) was added dropwise at 0° C., and the mixture was stirred at room temperature overnight. The reaction mixture was stirred into ice-water, and the mixture was extracted several times with dichloromethane. The collected organic phase was washed with saturated brine, dried over magnesium sulfate and concentrated under reduced pressure.
B) The intermediate from Step A was mixed with 500 ml of 5-6 M HCl in isopropanol and stirred at room temperature for 4 hours. After cooling to 0° C., the precipitate was filtered off, washed with isopropanol and diethyl ether and dried. 37 g of the desired product were obtained.
A 1.6 M solution of n-butyllithium in hexane (35 ml, 56 mmol) was added dropwise to a solution of benzothiazole (6.2 ml, 56 mmol) in THF (100 ml) at −78° C. After stirring at −78° C. for 1.5 h, the solution of the lithiated benzothiazole was transferred via a needle into an ice-cold suspension of 5-chloroisatin (3.63 g, 20 mmol) in THF (70 ml). The reaction mixture was stirred at 0° C. for 1 h and then saturated ammonium chloride solution was added. The mixture was extracted three times with ethyl acetate and the combined organic layers were washed with saturated brine. The organic phase was dried over magnesium sulfate, filtered and concentrated under reduced pressure, during which the intermediate starts to crystallize. Filtration and drying yielded 4.47 g of the intermediate as yellow crystalline solid.
Pyridine (0.57 ml) and thionyl chloride (0.42 ml) were successively added to an ice-cooled solution of the intermediate from Step A (1.27 g, 4.0 mmol) in dichloromethane (40 ml). The reaction mixture was stirred at 0° C. for 1 h and then saturated ammonium chloride solution was added. The organic phase was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude intermediate was rapidly employed without further purification in the next step.
(2S,4R)-4-hydroxy-pyrrolidine-2-carboxylic acid dimethylamide hydrochloride (0.78 g, 4.0 mmol) was added to a solution of the intermediate from Step B in a mixture of dichloromethane (9 ml), THF (2 ml) and DIPEA (2 ml). The reaction mixture was stirred at room temperature for 48 h. After addition of water, the mixture was extracted four times with ethyl acetate. The combined organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The less polar diastereomer, as judged by thin-layer-chromatography using 5% MeOH in dichloromethane, precipitated on concentration and was filtered off. Purification by chromatography (silica gel, 5% MeOH in dichloromethane) resulted in 0.28 g of the less polar diastereomer. Purification by chromatography (silica gel, 5% MeOH in dichloromethane) of the mother liquor resulted in 0.36 g of the more polar diastereomer.
Sodium hydride (12 mg of 60% dispersion in mineral oil, 0.3 mmol) was added to an ice-cold solution of the less polar diastereomer intermediate from Step C (115 mg, 0.25 mmol) in DMF (1.5 ml). The reaction mixture was stirred at 0° C. for 1 h and then 2,4-dimethoxy-benzene-sulfonyl chloride (71 mg, 0.3 mmol) was added. After the reaction mixture had been stirred at room temperature for one hour, water was added and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine and dried over magnesium sulfate. Purification by chromatography (silica gel, 5% MeOH in dichloromethane) resulted in 93 mg of Example 1 as a white solid.
1H NMR (400 MHz, DMSO-d6) δ 8.15 (1H), 7.95 (1H), 7.75 (2H), 7.50 (3H), 7.20 (1H), 6.80 (1H), 6.75 (1H), 4.80 (1H), 4.25 (1H), 3.90 (3H), 3.85 (1H), 3.50 (3H), 3.25 (1H), 2.60 (3H), 1.85 (1H), 1.75 (1H); MS (API-ES, pos) m/z=657 [M+H]
The diastereomer product was prepared by the method described in the previous paragraph starting from the more polar diastereomer intermediate from Step C. Purification by chromatography (silica gel, 5% MeOH in dichloromethane) resulted in Example 2 as a white solid.
1H NMR (400 MHz, DMSO-d6) δ 8.10 (1H), 7.95 (1H), 7.75 (1H), 7.65 (1H), 7.45 (4H), 6.80 (1H), 6.75 (1H), 4.85 (1H), 4.70 (1H), 4.30 (1H), 3.90 (3H), 3.60 (1H), 3.40 (3H), 2.83 (1H), 2.55 (3H), 2.45 (3H), 2.10 (1H), 1.80 (1H); MS (API-ES, pos) m/z=657 [M+H]
A 1.6 M solution of n-butyllithium in hexane (10 ml, 16 mmol) was added dropwise to a solution of 5-bromo-2,4-dimethoxypyrimidine (3.29 g, 15 mmol) in THF (50 ml) at −78° C. After stirring at −78° C. for 0.5 h, a suspension of 5-chloroisatin (1.27 g, 7.0 mmol) in THF (50 ml) was added dropwise. The reaction mixture was allowed to warm to room temperature and then saturated ammonium chloride solution was added. The mixture was extracted three times with ethyl acetate, and the combined organic layers were washed with saturated brine. The organic phase was dried over magnesium sulfate, filtered and concentrated under reduced pressure. Purification by chromatography (silica gel, 50% ethyl acetate in dichloromethane) resulted in 0.97 g of the intermediate.
Pyridine (0.28 ml) and thionyl chloride (0.18 ml) were added successively to an ice-cold solution of the intermediate from Step A (0.64 g, 2.0 mmol) in dichloromethane (20 ml). The reaction mixture was stirred at 0° C. for 1 h and then saturated ammonium chloride solution was added. The organic phase was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude intermediate was rapidly employed without further purification in the next step.
(2S,4R)-4-Hydroxy-pyrrolidine-2-carboxylic acid dimethylamide hydrochloride (0.39 g, 2.0 mmol) was added to a solution of the intermediate from Step B in a mixture of dichloromethane (4 ml), THF (1 ml) and DIPEA (1 ml). The reaction mixture was stirred at room temperature for 18 h. After addition of water, the mixture was extracted four times with ethyl acetate. The combined organic phase was dried over magnesium sulfate, filtered and concentrated under reduced pressure. Purification by chromatography (silica gel, 7% MeOH in dichloromethane) resulted in 0.45 g of the mixture of diastereomers (ratio about 2:1).
Sodium hydride (12 mg of 60% dispersion in mineral oil, 0.3 mmol) was added to an ice-cold solution of the mixture of diastereomers from Step C (139 mg, 0.30 mmol) in DMF (1.5 ml). The reaction mixture was stirred at 0° C. for 0.5 h and then 2,4-dimethoxy-benzenesulfonyl chloride (71 mg, 0.3 mmol) was added. After the reaction mixture had been stirred at room temperature for one hour, water was added, and the mixture was extracted with ethyl acetate.
The organic layer was washed with water and saturated brine and dried over magnesium sulfate. Purification by chromatography (silica gel, 5% MeOH in dichloromethane) resulted in 63 mg of the less polar diastereomer (levorotatory isomer) and 25 mg of the more polar diastereomer (dextrorotatory isomer) as colorless waxes.
This diastereomer is the less polar diastereomer from Step D.
1H NMR (400 MHz, DMSO-d6) δ 8.80 (1H), 7.97 (1H), 7.75 (1H), 7.45 (1H), 7.20 (1H), 6.75 (2H), 4.95 (1H), 4.55 (1H), 4.30 (1H), 3.90 (6H), 3.75 (3H), 3.37 (3H), 3.05 (1H), 1.75 (1H), 1.65 (1H); MS (API-ES, pos) m/z=662 [M+H]
This diastereomer is the more polar diastereomer from Step D.
1H NMR (400 MHz, DMSO-d6) δ 8.95 (1H), 7.95 (1H), 7.80 (1H), 7.50 (1H), 6.80 (2H), 6.70 (1H), 4.70 (1H), 4.20 (1H), 3.90 (6H), 3.75 (3H), 3.65 (1H), 3.40 (3H), 3.00 (1H), 2.80 (1H), 2.65 (3H), 2.45 (3H), 1.70 (2H); MS (API-ES, pos) m/z=662 [M+H]
A 1.7 M solution of tert-butyllithium in pentane (28.9 ml, 49.1 mmol) was added to THF (100 ml) at −78° C. 2-Bromomesitylene (3.6 ml, 23.4 mmol) was added dropwise and the mixture stirred at −78° C. for 1 h. 2-Methoxypyridine (1.92 ml, 18 mmol) was added at −78° C. and then the mixture was stirred at 0° C. for 1 h and at ambient temperature for 0.5 h. A suspension of 5-chloroisatin (1.27 g, 9.0 mmol) in THF (50 ml) was added dropwise at −78° C. The reaction mixture was allowed to warm to room temperature and then saturated ammonium chloride solution was added. The mixture was extracted three times with ethyl acetate, and the collected extracts were washed with saturated brine. The organic phase was dried over magnesium sulfate, filtered and concentrated under reduced pressure. Purification by crystallization from dichloromethane yielded 1.1 g of the intermediate.
Pyridine (0.33 ml) and thionyl chloride (0.30 ml) were added successively to an ice-cold solution of the intermediate from Step A (1.1 g, 3.44 mmol) in dichloromethane (10 ml). The reaction mixture was stirred at 0° C. for 1 h and then saturated ammonium chloride solution was added. The organic phase was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude intermediate was rapidly employed without further purification in the next step.
(2S,4R)-4-Hydroxy-pyrrolidine-2-carboxylic acid dimethylamide hydrochloride (0.67 g, 3.44 mmol) was added to a solution of the intermediate from Step B in a mixture of dichloromethane (10 ml), THF (2 ml) and DIPEA (1.6 ml). The reaction mixture was stirred at room temperature for 18 h. After addition of water, the mixture was extracted four times with ethyl acetate. The combined organic phase was dried over magnesium sulfate, filtered and concentrated under reduced pressure. Purification by chromatography (silica gel, 5% MeOH in dichloromethane) resulted in 0.58 g of the more polar diastereomer, 0.2 g of the less polar diastereomer and 0.4 g of a mixture of diastereomers (ratio about 1:1).
Sodium hydride (14.4 mg of 60% dispersion in mineral oil, 0.36 mmol) was added to an ice-cold solution of the more polar diastereomer intermediate from Step C (150 mg, 0.35 mmol) in DMF (3.2 ml). The reaction mixture was stirred at 0° C. for 1 h and then 2,4-dimethoxy-benzenesulfonyl chloride (86.2 mg, 0.364 mmol) was added. After the reaction mixture had been stirred at room temperature for one hour, water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and brine and dried over magnesium sulfate. Purification by chromatography (silica gel, 5% MeOH in dichloromethane) and trituration with diethyl ether (6 ml) and hexane (6 ml) resulted in 130 mg of the levorotatory diastereomer as a white solid.
[α]D20° C. (c=0.1, CHCI3): −233;
1H NMR (400 MHz, DMSO-d6) δ 8.20 (1H), 8.10 (1H), 8.00 (1H), 7.80 (1H), 7.45 (1H), 7.00 (2H), 6.75 (2H), 4.95 (1H), 4.55 (1H), 4.35 (1H), 3.85 (3H), 3.75 (3H), 3.35 (3H), 3.00 (1H), 2.55 (3H), 2.45 (3H), 1.65 (2H); MS (API-ES, pos) m/z=631 [M+H]
The diastereomer product was prepared by the method described in the previous paragraph starting from the less polar diastereomer intermediate from Step C. Purification by chromatography (silica gel, 5% MeOH in dichloromethane) and trituration with diethyl ether/hexane resulted in the dextrorotatory diastereomer as a white solid.
[α]D20° C. (c=0.1, CHCI3): +142;
1H NMR (400 MHz, DMSO-d6) δ 8.45 (1H), 8.13 (1H), 7.97 (1H), 7.80 (1H), 7.50 (1H), 7.20 (1H), 6.80 (2H), 6.55 (1H), 4.70 (1H), 4.25 (1H), 3.90 (3H), 3.80 (3H), 3.65 (1H), 3.35 (3H), 3.00 (1H), 2.75 (1H), 2.65 (3H), 2.40 (3H), 1.70 (2H); MS (API-ES, pos) m/z=631 [M+H]
The following compounds can be prepared in an analogous fashion to Examples 1 to 6 employing the synthetic route that is outlined in synthesis Scheme 1:
A 1.7 M solution of tert-butyllithium in pentane (57.8 mL) was added to THF (200 ml) at −78° C. 2-Bromomesitylene (3.6 mL) was added dropwise, keeping the temperature below −60° C., and the mixture stirred at −78° C. for 1 h. 3-Methoxypyridine (3.6 mL) was added dropwise at −78° C. and then the mixture was stirred between −30° C. and −20° C. The reaction mixture was re-cooled to −78° C. and a slurry of 5-chloroisatin (3.26 g) in THF (100 mL) was added portionwise, keeping the temperature below −60° C. The reaction mixture was stirred at −78° C. for 1 h. The cooling bath was removed and the reaction mixture was stirred for 30 min. The reaction mixture was quenched with 10% aqueous ammonium chloride solution and extracted several times with ethyl acetate. The combined organic layers were washed with water, dried over magnesium sulfate and evaporated to low volume. Upon standing, 1.05 g of a cream-colored solid separated which was filtered off, washed with ethyl acetate and dried in vacuo.
The subsequent steps were performed in analogous fashion to Examples 5 and 6.
1H NMR (400 MHz, DMSO-d6) δ 8.15 (1H), 7.95 (1H), 7.75 (1H), 7.43 (3H), 6.90 (1H), 6.75 (2H), 5.75 (1H), 4.70 (1H), 4.20 (1H), 3.90 (3H), 3.75 (3H), 3.25 (3H), 3.05 (1H), 2.70 (3H), 2.45 (3H), 1.95 (1H), 1.60 (1H); MS (API-ES, pos) m/z 631 [M+H]
A 1.7 M solution of tert-butyllithium in pentane (43.4 mL) was added to THF (150 ml) at −78° C. 2-Bromomesitylene (5.4 mL) was added dropwise, keeping the temperature below −60° C., and the mixture stirred at −78° C. for 1 h. 4-Methoxypyridine (2.75 mL) was added dropwise at −78° C. and then the mixture was stirred at −30° C. to −20° C. for 3.5 h. The reaction mixture was re-cooled to −78° C. and a slurry of 5-chloroisatin (2.44 g) in THF (120 ml) was added portionwise, keeping the temperature below −65° C. The reaction mixture was stirred at −78° C. for 30 min. The reaction mixture was allowed to warm to −20° C. and then 10% aqueous ammonium chloride solution (75 mL) was added. After stirring for 10 min, the white solid was filtered off, washed with water (excess) and ethyl acetate (20 mL). Yield after drying in vacuo: 1.8 g (42%).
MS (API-ES, pos) m/z=383 [M+H]
The subsequent steps were performed in analogous fashion to Examples 5 and 6.
1H NMR (400 MHz, DMSO-d6) δ 8.85 (1H), 8.40 (1H), 8.00 (1H), 7.75 (1H), 7.45 (1H), 7.05 (1H), 6.95 (1H), 6.75 (2H), 4.95 (1H), 4.60 (1H), 4.35 (1H), 3.85 (3H), 3.75 (3H), 3.35 (3H), 3.00 (1H), 2.55 (3H), 2.45 (3H), 1.60 (2H); MS (API-ES, pos) m/z=631 [M+H]
n-BuLi (26 mmol, 16.3 mL of a 1.6M solution in hexanes) was added dropwise to a solution of 2,2,6,6-tetramethylpiperidine (26 mmol, 4.4 mL) in THF (150 mL) at 0° C. After stirring for 30 min at 0° C., the solution was cooled to −78° C. and a solution of 2-methoxypyrazine (20 mmol, 1.93 mL) in THF (30 mL) was added dropwise. After stirring at −78° C. for 15 min, a suspension of 5-chloroisatin (10 mmol, 1.82 g) in THF (50 mL) was added. The reaction mixture was stirred at 0° C. for 2 h, then saturated ammonium chloride solution was added. The mixture was extracted three times with ethyl acetate, and the collected extracts were washed with saturated brine. The organic phase was dried over magnesium sulfate, filtered and concentrated under reduced pressure. Purification by crystallization from diethyl ether yielded 1.14 g of the required intermediate.
The subsequent steps were performed in analogous fashion to Examples 5 and 6.
1H NMR (500 MHz, DMSO-d6) δ 8.23 (1H), 8.17 (1H), 7.95 (1H), 7.75 (1H), 7.47 (1H), 7.15 (1H), 6.75 (2H), 5.05 (1H), 4.65 (1H), 4.25 (1H), 3.87 (3H), 3.67 (3H), 3.50 (3H), 3.00 (1H), 2.65 (3H), 1.90 (1H), 1.65 (1H); MS (API-ES, pos) m/z=632 [M+H]
Magnesium turnings (40 g, 1.65 mol) are introduced into diethyl ether (100 ml) and, while stirring, a solution of 2-bromoanisole (206 ml, 1.65 mol), in diethyl ether (450 ml) is added dropwise. The reaction can be initiated, if necessary, by adding iodine crystals. During the addition, the reaction mixture should boil gently. After the addition, the mixture was stirred at room temperature for 1 hour. A slurry of 5-chloroisatin (75 g, 0.41 mol) in THF (750 ml) was added to the Grignard solution while cooling slightly (temperature 18-24° C.), and the mixture was stirred at room temperature for 30 min. The reaction mixture was stirred into ammonium chloride solution and extracted several times with ethyl acetate. The combined organic phase was washed four times with water, dried over magnesium sulfate and concentrated under reduced pressure. The remaining residue was stirred with 2-propanol. The resulting precipitate was filtered off, washed with 2-propanol and diethyl ether and dried. 106 g of the desired intermediate were obtained.
Pyridine (56 ml) and thionyl chloride (38 ml) were successively added dropwise to an ice-cold solution of the intermediate from Step A (100 g, 0.345 mol) in dichloromethane (1 000 ml). The reaction mixture was stirred at 0° C. for 30 min and then stirred into ice-water. The organic phase was separated, and the aqueous phase was extracted once more with dichloromethane. The combined organic phase was washed several times with water, dried over magnesium sulfate and concentrated under reduced pressure. The residue was stirred with hot toluene. The resulting crystals were filtered off in the cold, washed with toluene and pentane and dried. 79 g of the desired 3-chloro intermediate were obtained.
(2S,4R)-4-Hydroxy-pyrrolidine-2-carboxylic acid dimethylamide hydrochloride (12.6 g, 65 mmol) was added to a solution of the 3-chloro intermediate (20.0 g, 65 mmol) in dichloromethane (400 ml) and DIPEA (28 ml, 162 mmol). The solution was stirred at room temperature overnight. The reaction mixture was diluted with dichloromethane and washed with dilute sodium bicarbonate and several times with water. The organic phase was dried over magnesium sulfate and concentrated under reduced pressure. The residue was recrystallized from acetone. 6.5 g of the less polar (as judged by thin-layer-chromatography on silica gel, 7% MeOH in dichloromethane) diastereomer were obtained. The mother liquor was concentrated under reduced pressure. Purification of the remaining residue by chromatography (silica gel, 7% MeOH in dichloromethane) resulted in 1.0 g of the less polar diastereomer and 17.3 g of the more polar diastereomer.
Potassium tert-butoxide (38 mg, 0.34 mmol) was added to an ice-cold solution of the more polar diastereomer from Step B (150 mg, 0.34 mmol) in DMF (3 ml), and the mixture was stirred at 0° C. for 30 min. After addition of 8-quinolinesulfonyl chloride (79 mg, 0.34 mmol), the reaction mixture was left to stir at room temperature for 3 hours. Water was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was washed with water and saturated brine and dried over magnesium sulfate. Purification by chromatography (silica gel, 7% MeOH in dichloromethane) resulted in 159 mg of the product.
[α]D20° C. (c=0.20, CHCI3): −148;
1H-NMR (D6-DMSO): δ=1.4-1.6 (5H), 1.7 (2H), 1.9 (2H), 2.15-2.35 (4H), 2.45 (3H), 2.9 (2H), 3.25 (4H), 3.7 (3H), 4.15 (2H), 6.55 (1H), 6.6 (1H), 6.75-6.90 (3H), 7.05-7.2 (2H), 7.40 (1H), 7.65 (1H), 7.9 (1H), 8.0 (1H), 8.15 (1H) and 8.85 (1H) ppm; MS (API-ES, pos) m/z=621 [M+H]
Examples 29 to 61 can be prepared in analogous fashion to Example 28 using Example 28B (more polar diastereomer) as the starting material in the sulfonylation reaction. Heterocyclic sulfonyl chlorides were acquired from commercial suppliers or synthesized according to standard methods, for example according to the following procedure:
Chlorine gas was bubbled through a solution of 2-mercapto-5-methylpyridine (64 mmol, 8.00 g, from Ubichem) in conc. hydrochloric acid (80 mL) at 0° C. After 1 h, the reaction mixture was poured into an ice-water mixture (200 mL). The suspension was extracted several times with dichloromethane and the combined organic layers were washed with sodium, bicarbonate solution. After drying over sodium sulfate, the volatiles were evaporated in vacuo to yield 9.80 g (80%) of atolorless oil which solidified in the refrigerator.
5-Trifluoromethyl-pyridine-2-sulfonyl chloride, 5-Bromo-pyridine-2-sulfonyl chloride, 5-Bromo-3-methyl-pyridine-2-sulfonyl chloride, Pyridine-2-sulfonyl chloride, 4-Methyl-pyridine-2-sulfonyl chloride, 6-Methyl-pyridine-2-sulfonyl chloride, 5-Chloro-pyridine-2-sulfonyl chloride were prepared in analogous fashion.
1H-NMR (D6-DMSO): δ=1.65 (1H), 2.05 (1H), 2.4-2.6 (6H), 2.8 (1H), 3.0 (3H), 3.1 (1H), 4.3 (1H), 4.45 (1H), 4.95 (1H, OH), 6.8 (1H), 6.9 (1H), 7.0 (1H), 7.25-7.35 (2H), 7.4 (1H), 7.65 (1H) and 8.0-8.2 (3H) ppm; MS (API-ES, pos) m/z=576 [M+H]
[α]D20° C. (c=0.12, CHCI3): −131;
1H-NMR (D6-DMSO): δ=1.7 (1H), 2.0 (1H), 2.35-2.55 (6H), 2.65 (1H), 2.95 (1H), 3.2 (3H), 4.25 (1H), 4.45 (1H), 4.7 (broad, 1H, OH), 6.8 (1H), 6.9 (1H), 7.0 (1H), 7.25 (1H), 7.30 (1H), 7.35 (1H), 7.60 (1H), 7.90 (1H) and 8.05 (1H) ppm.
[α]D20° C. (c=0.17, CHCI3): −142;
1H-NMR (CDCI3) δ=1.75 (1H), 1.9 (1H), 2.3 (1H), 2.4 (3H), 2.75 (3H), 3.3 (1H), 3.6 (3H), 4.65 (1H), 4.8 (1H), 6.8 (1H), 7.0 (2H), 7.1 (1H), 7.3 (1H), 7.8 (1H) and 7.9 (1H) ppm.
[α]D20° C. (c=0.18, CHCI3): −146;
1H-NMR (D6-DMSO): S=1.65 (1H), 2.0 (1H), 2.3-2.5 (7H), 2.75 (1H), 2.85 (3H), 4.3 (1H), 4.45 (1H), 4.9 (1H, OH), 6.8 (1H), 6.95 (1H), 7.0 (1H), 7.25 (1H), 7.45 (1H), 7.55 (1H), 7.6 (1H), 7.7 (1H), 8.05 (1H), 8.1 (1H), 8.15 (1H), and 8.55 (1H) ppm.
[α]D20° C. (c=0.19, CHCI3): −104;
1H-NMR (CDCI3): δ=1.7 (2H), 2.4 (3H), 2.5-2.8 (4H), 2.9 (3H), 3.3-3.5 (4H), 4.55 (1H), 4.7 (1H), 6.7 (1H), 7.0 (1H), 7.1 (1H), 7.25 (1H), 7.45 (1H), 7.75 (1H) and 7.7-7.9 (3H) ppm.
[α]D20° C. (c=0.20, CHCI3): −152;
1H-NMR (D6-DMSO): δ=1.7 (2H), 2.3-2.5 (8H), 3.1 (3H), 3.75 (3H), 4.35 (1H), 4.55 (1H), 4.9 (1H, OH), 6.85 (1H), 6.9 (1H), 7.0 (1H), 7.3 (1H), 7.4 (1H), 7.75 (1H), 7.85 (1H) and 8.25 (1H) ppm.
[α]D20° C. (c=0.20, CHCI3): −161
[α]D20° C. (c=0.21, CHCI3): −152;
1H-NMR (CDCI3) δ=1.75 (1H), 1.9 (1H), 2.4 (3H), 2.6-2.9 (10H), 3.3 (1H), 3.5 (3H), 4.6 (1H), 4.75 (1H), 6.75 (1H), 6.95 (1H), 7.1 (1H), 7.2 (2H), 7.8 (1H) and 7.9 (1H) ppm; MS (API-ES, pos) m/z=605 [M+H]
[α]D20° C. (c=0.22, CHCI3): −127;
MS (API-ES, pos) m/z=650 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.80 (1H), 8.35 (1H), 8.25 (1H), 8.00 (1H), 7.80 (2H), 7.45 (1H), 7.30 (1H), 7.00 (1H), 6.95 (1H), 6.85 (1H), 4.95 (1H), 4.50 (1H), 4.30 (1H), 3.10 (3H), 2.45 (4H), 1.65 (1H); MS (API-ES, pos) m/z=571 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.95 (1H), 8.50 (1H), 8.30 (1H), 8.00 (1H), 7.77 (1H), 7.40 (1H), 7.30 (1H), 7.03 (1H), 6.97 (1H), 6.90 (1H), 4.90 (1H), 4.45 (1H), 4.30 (1H), 3.27, 2.40 (4H), 1.60 (1H); MS (API-ES, pos) m/z=649 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.63 (1H), 8.25 (1H), 8.00 (2H), 7.80 (1H), 7.40 (1H), 7.25 (1H), 7.00 (1H), 7.95 (1H), 6.85 (1H), 4.90 (1H), 4.50 (1H), 4.30 (1H), 3.15, 2.45 (7H), 1.65 (1H); MS (API-ES, pos) m/z=585 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.85 (1H), 8.35 (2H), 8.00 (1H), 7.75 (1H), 7.40 (1H), 7.30 (1H), 7.00 (2H), 6.40 (1H), 4.90 (1H), 4.40 (1H), 4.30 (1H), 3.30, 2.40, 1.60 (1H); MS (API-ES, pos) m/z=605 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.75 (1H), 8.40 (1H), 8.00 (1H), 7.70 (1H), 7.40 (1H), 7.30 (1H), 7.00 (2H), 6.93 (1H), 5.00 (1H), 4.50 (1H), 4.35 (1H), 3.45 (3H), 2.80 (3H), 2.35, 1.65 (1H); MS (API-ES, pos) m/z=663 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.43 (1H), 7.95 (1H), 7.85 (1H), 7.75 (1H), 7.40 (1H), 7.30 (1H), 7.00 (2H), 6.90 (1H), 4.95 (1H), 4.55 (1H), 4.40 (1H), 3.40 (3H), 2.75 (3H), 2.35, 1.63 (1H); MS (API-ES, pos) m/z=599 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 9.33 (1H), 8.90 (1H), 8.60 (1H), 8.10 (1H), 7.75 (2H), 7.40 (1H), 7.30 (1H), 7:05 (1H), 7.00 (1H), 6.85 (1H), 4.95 (1H), 4.45 (1H), 4.20 (1H), 3.20 (3H), 3.15 (1H), 2.70 (1H), 2.30 (3H), 2.00 (1H), 1.60 (1H); MS (API-ES, pos) m/z=571 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.75 (1H), 8.12 (1H), 8.00 (1H), 7.70 (1H), 7.37 (1H), 7.30 (1H), 7.00 (2H), 6.93 (1H), 6.87 (1H), 4.90 (1H), 4.47 (1H), 4.25 (1H), 3.65 (8H), 3.20 (3H), 2.30-2.45 (5H), 2.00 (1H), 1.65 (1H); MS (API-ES, pos) m/z=656 [M+H]
(−)-(2S,4R)-1-{5-Chloro-3-(2-methoxy-phenyl)-2-oxo-1-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl]-2,3-dihydro-1H-indol-3-yl}-4-hydroxy-pyrrolidine-2-carboxylic acid dimethylamide (obtained from Example 28B (more polar diastereomer) and commercially available 2-(2,2,2-Trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonyl chloride) (1.39 mmol, 1.00 g) was deprotected using K2CO3 (1 eq.) at RT for 6 h in a 9:1 MeOH:H2O mixture (22 mL). The solution was evaporated in vacuo. The residue was dissolved in a 1:1 CH2Cl2:H2O mixture and the phases were separated. The organic phase was dried over magnesium sulfate and evaporated in vacuo to afford 850 mg of the required product.
1H-NMR (400 MHz, DMSO-d6) δ 9.06 (2H, s br.), 8.22-7.91 (3H, m), 7.72 (1H, d), 7.56 (1H, d), 7.38 (1H, d), 7.27 (1H, t), 7.02 (1H, t), 6.96 (1H, s), 6.83 (1H, d), 3.40 (2H, s br.), 3.08 (2H, t), 3.02 (2H, s br.), 2.05 (1H, m br.), 1.72-1.57 (1H, m); MS (API-ES, pos) m/z=625 [M+H]
Magnesium turnings (6.8 g, 0.27 mmol) are introduced into diethyl ether (30 ml), and, while stirring, a solution of 2-bromo-3-methyl-thiophene (50 g, 0.282 mol) in diethyl ether (100 ml) is added dropwise. The reaction can be initiated if necessary by adding iodine crystals. During the addition, the reaction mixture should boil gently. After the addition, the mixture was stirred at room temperature for 1 hour. A suspension of 5-chloroisatin (19 g, 0.105 mol) in THF (200 ml) was added to the Grignard solution while cooling slightly (temperature 18-24° C.) and the mixture was stirred at room temperature for 30 min. The reaction mixture was stirred into ammonium chloride solution and extracted several times with ethyl acetate. The combined organic phases were washed with saturated brine, dried over magnesium sulfate and concentrated under reduced pressure. The residue was stirred with diethyl ether. The resulting precipitate was filtered off, washed with diethyl ether and dried. 26 g of the desired intermediate were obtained.
Potassium tert-butoxide (1.21 g, 10.8 mmol) was added to an ice-cold solution of the intermediate from Step A (3.00 g, 10.8 mmol) in DMF (30 ml), and the mixture was stirred at 0° C. for 30 min. After addition of 2,4-dimethoxy-benzenesulfonyl chloride (2.5 g, 10.8 mmol), the reaction mixture was left to stir at 0° C. for 1 hour. Further addition of 0.2 equivalent each of potassium tert-butoxide and sulfonyl chloride led to no further advance in the reaction according to thin-layer chromatography. The reaction mixture was stirred into dilute potassium carbonate solution, and the resulting precipitate was filtered off. The precipitate was taken up in ethyl acetate, and the extract was washed with saturated brine and dried over magnesium sulfate. Purification by chromatography (silica gel, gradient 30% to 50% ethyl acetate in heptane) and recrystallization from diethyl ether resulted in 0.96 g of the desired product.
1H-NMR (D6-DMSO) δ=1.55 (3H), 3.6 (3H), 3.85 (3H), 6.7 (1H), 6.75 (2H), 7.2 (1H), 7.35 (1H), 7.55 (1H), 7.6 (1H), 7.8 (1H) and 7.9 (1H) ppm.
4-Chlorophenyl isocyanate (32 mg, 0.208 mmol) and DMAP (5 mg) were successively added to a solution of Example 62 (100 mg, 0.21 mmol) in toluene (20 ml) and stirred at 90° C. for 30 min. The solvent was removed under reduced pressure, and the residue was taken up in ethyl acetate. The organic phase was washed with dilute citric acid solution and saturated sodium chloride solution, dried over magnesium sulfate and concentrated under reduced pressure. Recrystallization from methanol resulted in 80 mg of the desired product.
1H-NMR (D6-DMSO) δ=1.95 (3H), 3.85 (3H), 3.9 (3H), 6.6 (1H), 6.7 (1H), 6.75 (1H), 7.05 (1H), 7.7 (1H), 7.4-7.5 (2H), 7.6-7.75 (5H) and 9.25 (1H) ppm.
Potassium tert-butoxide (0.81 g, 7.25 mmol) was added to an ice-cold solution of Example 28A (2.00 g, 6.90 mmol) in DMF (24 ml), and the mixture was stirred at 0° C. for 60 min. After addition of 8-quinoline-sulfonyl chloride (1.65 g, 7.25 mmol), the reaction mixture was left to stir at 0° C. for 2 hours and then at room temperature overnight. The reaction mixture was stirred into dilute potassium carbonate solution, and the resulting precipitate was filtered off, washed with water and dried. Purification by chromatography (silica gel, 10% MeOH in dichloromethane) resulted in 1.8 g of the product.
1H-NMR (D6-DMSO) δ=2.75 (3H), 6.75 (1H), 6.8 (1H), 7.05 (1H), 7.1 (1H), 7.3 (1H), 7.55 (1H), 7.7 (1H), 7.75 (1H), 7.9 (1H), 8.2 (1H), 8.45 (1H), 8.6 (1H), 8.65 (1H) and 8.85 (1H) ppm.
Phenyl chloroformate (0.35 ml, 2.79 mmol) was added dropwise to a solution of Example 64 (300 mg, 0.624 mmol) in pyridine (6 ml) while cooling slightly. The reaction mixture was stirred at room temperature overnight. After addition of ice-water, the mixture was extracted with ethyl acetate, and the organic phase was washed several times with dilute citric acid solution and water. The organic phase was dried over magnesium sulfate and concentrated under reduced pressure. The residue was triturated with diethyl ether, and the resulting precipitate was filtered off, washed with diethyl ether and dried. 310 mg of the desired intermediate were obtained.
Piperidine (0.132 ml, 1.33 mmol) was added to a solution of the intermediate from Step A (200 mg, 0.33 mmol) in THF (10 ml), and the reaction solution was stirred overnight. 2 M sodium hydroxide solution was added to the reaction mixture, which was then extracted with dichloromethane. The organic phase was washed three times with water and concentrated under reduced pressure. Recrystallization from dichloromethane/diethyl ether resulted in 112 mg of the desired product.
1H-NMR (D6-DMSO) δ=1.2 (2H), 2.85 (2H), 3.3 (3H), 3.5 (2H), 6.9 (1H), 7.05 (1H), 7.1 (1H), 7.35 (1H), 7.5 (1H), 7.6-7.7 (2H), 7.8 (1H), 8.1 (1H), 8.4 (1H), 8.55 (1H), 8.6 (1H) and 8.8 (1H) ppm.
1H-NMR (D6-DMSO): δ=1.35 (2H), 1.65 (2H), 1.8 (2H), 2.05-2.2 (4H), 2.25 (2H), 2.45 (2H), 2.75 (2H), 2.85 (2H), 3.3 (3H), 3.45 (1H), 3.55 (1H), 6.90 (1H), 7.05 (1H), 7.15 (1H), 7.35 (1H), 7.5 (1H), 7.6-7.7 (2H), 7.8 (1H), 8.10 (1H), 8.4 (1H), 8.55 (1H), 8.65 (1H), 8.8 (1H) and 10.9 (broad) ppm.
1H NMR (400 MHz, DMSO-d6) δ 8.20 (2H), 8.10 (2H), 7.80 (2H), 7.70 (2H), 7.50 (1H), 7.30 (1H), 7.20 (1H), 3.60 (2H), 3.10 (2H), 2.75 (2H), 2.35 (2H), 2.15 (4H), 1.85 (2H), 1.70 (2H), 1.40 (4H); MS (API-ES, pos) m/z=640 [M+H]
Examples 77 to 82 bearing an amide moiety in the 3-position of the oxindole core were prepared employing synthetic methods that are outlined in synthetic Scheme 3:
N-[5-Chloro-3-(2-methoxy-phenyl)-2-oxo-1-(quinoline-8-sulfonyl)-2,3-dihydro-1H-indol-3-yl]-acetamide
1H-NMR (D6-DMSO): δ=1.8 (3H), 3.55 (3H), 6.75 (1H), 7.0 (1H), 7.05 (1H), 7.2-7.35 (1H), 7.65 (1H), 7.85 (1H), 7.95 (1H), 8.4 (1H), 8.55 (1H), 8.65 (1H), 8.75 (1H) and 8.95 (1H) ppm.
1H-NMR (D6-DMSO): δ=3.85 (3H), 6.45 (1H), 6.65 (1H), 6.85 (1H), 6.9 (1H), 7.15, 7.3 (3H), 7.35 (2H), 7.4-7.6 (2H), 7.75 (1H), 8.1-8.3 (4H), 8.6 (1H) and 8.75-8.85 (2H) ppm.
1H NMR (400 MHz, DMSO-d6) δ 9.05 (1H), 8.20 (1H), 8.15 (2H), 7.90 (1H), 7.70 (1H), 7.50 (1H), 7.40 (1H), 7.35 (1H), 7.00 (1H), 6.80 (2H), 6.65 (2H), 3.80 (8H), 3.50 (3H), 2.90 (2H), 1.75 (1H), 1.60 (1H), 1.35 (2H); MS (API-ES, pos) m/z=678 [M+H]
The procedure for the synthesis of Example 83 is representative for the synthesis of examples that bear a urea moiety in the 3-position of the oxindole.
40 g (1.65 mol) of magnesium chips and 5% of the total amount of the 2-bromo-1-ethoxy benzene were added to 100 ml diethyl ether and after adding a few crystals iodine the mixture was carefully heated to initiate the reaction. To the refluxing mixture the remaining amount of 203 ml (1.65 mol) 2-bromo-1-ethoxy benzene, dissolved in 450 ml diethyl ether, was added slowly to maintain the reaction. Then 75 g (0.41 mol) of 5-methoxyisatine, suspended in 750 ml THF, were added to the cooled reaction mixture. After stirring the reaction mixture for 30 minutes at ambient temperature, the mixture was poured into an ice/aqueous NH4Cl mixture. The aqueous phase was extracted with ethyl acetate several times and the combined organic phase was washed with H2O, dried over magnesium sulfate and the solvent was removed in vacuo.
5 g (16.7 mmol) of the intermediate from Step A and 2.6 g (33.4 mmol) pyridine were dissolved in 50 mL CH2Cl2 and at 0° C. 3 g (25.1 mmol) SOCl2 were added slowly. Then the reaction mixture was stirred for 30 min. at 0° C. The reaction mixture was poured into an ice/water mixture and the organic phase was separated, washed with H2O, dried over magnesium sulfate and finally the solvent was removed in vacuo. The resulting residue was suspended in ether. The solid residue was separated and dried to give 3.2 g of the intermediate, which was used without further purification.
3.2 g (10 mmol) of the intermediate from Step B were suspended in 40 ml CH2Cl2. 50 ml of a 2M solution of NH3 in ethanol were added and the reaction mixture was stirred for 16 h at ambient temperature. The mixture was poured into an ice/water mixture and the precipitate was separated. The precipitate was redissolved in ethyl acetate. This organic phase was washed with 2M aqueous HCl. The aqueous phase was made alkaline (pH=8-9) and then extracted with ethyl acetate. The organic phase was dried over magnesium sulfate and the solvent was removed in vacuo to yield 1.7 g of the intermediate.
1.8 g (6 mmol) of the intermediate from Step C were dissolved in 20 ml pyridine. At 0° C. 0.99 g (6.3 mmol) phenyl chloroformate were added and afterwards the reaction mixture was stirred for 1 h at 0° C. This mixture was poured into an ice/water mixture. The pH of the aqueous phase was adjusted to 5 and the resulting mixture was extracted with ethyl acetate. The organic phase was separated, dried over magnesium sulfate and the solvent was removed in vacuo. The resulting solid (2 g) was used in the next step without further purification.
1.9 g (4.5 mmol) of the intermediate from Step D and 1.75 g (9.5 mmol) 1-(1-methylpiperidine-4-yl)-piperazine were dissolved in 30 ml dry THF and refluxed for 90 minutes. The volatiles were removed in vacuo. The resulting residue was dissolved in ethyl acetate, washed with H2O and dried over magnesium sulfate and the solvent was removed in vacuo. The residue was treated with H2O and the resulting precipitate was separated to yield 1.5 g of the intermediate.
200 mg (0.39 mmol) of the intermediate from Step E were dissolved in 30 ml THF. At 0° C. 19 mg (0.43 mmol) NaH (55%) were added. After stirring the reaction mixture for 20 min, 99 mg (0.43 mmol) 1-quinoline-8-sulfonylchloride were added. The reaction mixture was stirred for 1 h. The solvent was removed in vacuo. The residue was recrystallized from CH3OH/H2O to obtain 180 mg of Example 83.
1H-NMR (CDCI3): δ=1.4-1.6 (5H), 1.7 (2H), 1.9 (2H), 2.15-2.35 (4H), 2.45 (3H), 2.9 (2H), 3.25 (4H), 3.7 (3H), 4.15 (2H), 6.55 (1H), 6.6 (1H), 6.75-6.90 (3H), 7.05-7.2 (2H), 7.40 (1H), 7.65 (1H), 7.9 (1H), 8.0 (1H), 8.15 (1H) and 8.85 (1H) ppm.
The following examples bearing a carbamate or urea moiety in the 3-position of the oxindole core can be synthesized in analogous fashion to Example 65 or Example 83, respectively.
1H-NMR (D6-DMSO): S=2.0-2.2 (5H), 2.75 (2H), 2.9 (2H), 3.3 (3H), 3.45 (1H), 3.65 (1H), 6.90 (1H), 7.05 (1H), 7.15 (1H), 7.35 (1H), 7.5 (1H), 7.6-7.75 (2H), 7.8 (1H), 8.1 (1H), 8.4 (1H), 8.55 (1H), 8.65 (1H) and 8.8 (1H) ppm.
1H-NMR (D6-DMSO): S=2.45 (3H), 2.95 (3H), 3.3 (3H), 6.90 (1H), 7.05 (1H), 7.15 (1H), 7.35 (1H), 7.5 (1H), 7.65 (1H), 7.75 (1H), 7.8 (1H), 8.1 (1H), 8.4 (1H), 8.55 (1H), 8.65 (1H) and 8.8 (1H) ppm.
1H-NMR (D6-DMSO): S=1.2-1.4 (4H), 1.6-1.85 (6H), 1.95 (1H), 2.1 (1H), 2.6 (1H), 2.8-3.0 (3H), 3.25 (3H), 3.3 (1H), 3.4 (1H), 4.2 (1H), 6.90 (1H), 7.05 (1H), 7.15 (1H), 7.35 (1H), 7.5 (1H), 7.6-7.75 (2H), 7.8 (1H), 8.15 (1H), 8.4 (1H), 8.55 (2H), 8.6 (1H), 8.8 (1H) and 9.9 (broad) ppm.
1H NMR (400 MHz, DMSO-d6) δ 8.20 (2H), 8.10 (2H), 7.80 (2H), 7.70 (2H), 7.50 (1H), 7.27 (1H), 7.20 (1H), 4.20 (1H), 3.55 (1H), 3.05 (1H), 2.65 (1H), 2.40 (8H), 2.15 (3H), 1.80 (1H), 1.65 (1H), 1.40 (1H), 1.10 (1H); MS (API-ES, pos) m/z=640 [M+H]
1H-NMR (D6-DMSO): δ=2.1 (2H), 2.3 (2H), 2.7 (3H), 2.8-3.9 (18H), 4.4 (1H), 6.7 (2H), 7.35 (2H), 7.5 (1H), 7.7-8.0 (4H), 8.3 (1H), and 11.5 (broad, N+H) and 11.8 (broad, N+H) ppm.
1H NMR (400 MHz, DMSO-d6) δ 8.20 (1H), 8.15 (1H), 7.90 (1H), 7.80 (1H), 7.50 (1H), 7.25 (1H), 7.15 (1H), 6.70 (2H), 3.85 (3H), 3.60 (7H), 3.50 (1H), 3.10 (2H), 2.80 (2H), 2.30 (2H), 2.15 (4H), 1.80 (2H), 1.65 (2H), 1.35 (4H); MS (API-ES, pos) m/z=700 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.20 (1H), 8.10 (1H), 7.90 (1H), 7.75 (1H), 7.40 (1H), 7.15 (1H), 7.10 (2H), 6.70 (2H), 3.85 (3H), 3.40-3.70 (8H), 3.10 (2H), 2.80 (2H), 2.40 (3H), 2.10 (3H), 1.80 (2H), 1.65 (2H), 1.35 (4H); MS (API-ES, pos) m/z=666 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.20 (2H), 7.90 (3H), 7.75 (1H), 7.17 (1H), 6.70 (2H), 3.85 (3H), 3.60 (4H), 3.55 (3H), 3.50 (1H), 3.10 (2H), 2.75 (2H), 2.30 (2H), 2.15 (4H), 1.80 (2H), 1.65 (2H), 1.20-1.50 (4H); MS (API-ES, pos) m/z=691 [M+H]
1H-NMR (400 MHz, CDCI3) δ 8.10 (2H, m), 7.92 (1H, d), 7.79 (1H, d), 7.14 (1H, d), 6.94 (1H, m), 6.76 (1H, s), 6.54 (1H, d), 6.41 (1H, s), 3.84 (6H, d), 3.63 (3H, s), 3.58 (2H, s br.), 3.17 (2H, br.), 2.92 (2H, d), 2.53 (2H, s br.), 2.40 (2H, s br.), 2.26 (3H, s), 2.24 (3H, s), 1.94 (2H, t), 1.85-1.47 (8H, m); MS (API-ES, pos) m/z=680 [M+H]
1H-NMR (D6-DMSO): δ=2.1 (2H), 2.3 (2H), 2.7 (6H), 3.0 (2H), 3.15 (1H), 3.3-4.0 (18H), 4.3 (1H), 6.6 (1H), 6.7 (1H), 6.9 (1H), 7.15 (1H), 7.3 (1H), 7.4 (1H), 7.7 (1H), 7.8 (1H), 8.6 (1H), 10.6 (broad, N+H) and 11.6 (broad, N+H) ppm.
MS (ESI, pos) m/z=658 [M+H]
MS (ESI, pos) m/z=658 [M+H]
MS (ESI, pos) m/z=665 [M+H]
MS (ESI, pos) m/z=670 [M+H]
MS (ESI, pos) m/z=670 [M+H]
MS (ESI, pos) m/z=674 [M+H]
MS (ESI, pos) m/z=674 [M+H]
MS (ESI, pos) m/z=674 [M+H]
MS (ESI, pos) m/z=677 [M+H]
MS (ESI, pos) m/z=682 [M+H]
MS (ESL pos) m/z=700 [M+H]
MS (ESI, pos) m/z=708 [M+H]
MS (ESI, pos) m/z=724 [M+H]
1H-NMR (CDCI3): δ=1.3 (3H), 1.6-1.8 (2H), 1.8-2.0 (4H), 2.2-2.6 (8h), 3.1 (2H), 3.2-3.4 (4H), 3.75 (6H), 4.2 (2H), 6.7-7.0 (7H), 7.2 (1H), 7.5 (1H), and 7.8 (1H) ppm.
1H-NMR (D6-DMSO): S=2.1 (2H), 2.3 (2H), 2.7 (3H), 2.8-3.8 (18H), 4.3 (1H), 6.7 (1H), 6.95 (2H), 7.05 (1H), 7.25 (1H), 7.35 (1H), 7.65 (1H), 7.95 (1H), 8.15 (1H), 10.8 (broad, N+H) and 11.8 (broad, N+H) ppm.
1H-NMR (D6-DMSO): S=2.0 (2H), 2.15 (3H), 2.3 (2H), 2.7 (3H), 2.9-3.8 (15H), 4.3 (1H), 6.85 (1H), 6.90 (1H), 7.1 (1H), 7.2 (1H), 7.35 (1H), 7.7 (1H), 7.8 (2H), 8.2 (2H), 10.6 (broad, and 11.7 (broad, N+H) ppm.
1H-NMR (D6-DMSO): S=1.4 (1H), 1.6 (1H), 2.0 (1H), 2.2 (3H), 2.65 (2H), 2.8 (3H), 3.0 (2H), 3.2-3.8 (12H), 4.3 (1H), 6.85 (1H), 6.9 (1H), 7.1 (1H), 7.15 (1H), 7.35 (1H), 7.7 (1H), 7.75 (1H), 8.2 (2H), and 8.8 (1H) ppm.
1H-NMR (D6-DMSO): S=2.1 (2H), 2.2 (3H), 2.3 (2H), 2.7 (3H), 2.9-3.8 (15H), 4.3 (1H), 6.9 (2H), 7.1 (1H), 7.2 (1H), 7.25 (1H), 7.35 (1H), 7.6 (1H), 7.8 (1H), 7.95 (1H), 8.1 (1H), 10.6 (broad, N+H) and 11.8 (broad, N+H) ppm.
1H-NMR (D6-DMSO): δ=1.4 (1H), 1.65 (1H), 2.0 (1H), 2.2 (3H), 2.7 (2H), 2.8 (3H), 3.0 (2H), 3.2-3.8 (12H), 4.35 (1H), 6.85 (2H), 6.0 (1H), 7.1 (1H), 7.15 (1H), 7.25 (1H), 7.35 (1H), 7.6 (1H), 7.8 (1H), 8.0 (1H) and 8.1 (1H) ppm.
1H-NMR (D6-DMSO): δ=2.0 (2H), 2.2-2.4 (8H), 2.7 (3H), 2.9-3.8 (12H), 4.3 (1H), 6.8 (1H), 7.1-7.2 (2H), 7.2-7.4 (4H), 7.7 (1H), 7.85 (1H), 8.1 (1H), 10.6 (broad, N+H) and 11.8 (broad, N+H) ppm.
1H-NMR (D6-DMSO): δ=1.5 (1H), 2.1 (1H), 2.25-2.4 (6H), 2.7 (2H), 2.8 (3H), 3.0 (2H), 3.2-3.9 (10H), 4.25 (1H), 6.75 (1H), 7.0-7.2 (2H), 7.2-7.4 (4H), 7.7 (1H), 7.8 (1H) and 8.1 (1H) ppm.
1H-NMR (D6-DMSO): δ=2.1 (2H), 2.2 (3H), 2.3 (3H), 2.7 (3H), 2.8-3.7 (14H), 3.9 (1H), 4.1 (1H), 6.9-7.1 (4H), 7.25 (1H), 7.3 (1H), 7.5 (1H), 7.85 (1H), 7.9 (1H), 8.1 (1H), 10.6 (broad, N+H) and 11.4 (broad, N+H) ppm.
1H-NMR (D6-DMSO): δ=1.9-2.1 (2H), 2.25 (2H), 2.4 (3H), 2.7 (3H), 2.8-3.8 (14H), 6.7 (1H), 7.15 (1H), 7.2-7.35 (2H), 7.75 (1H), 7.9 (1H), 8.05 (2H), 8.15 (2H), 8.6 (1H), 10.3 (broad, N+H) and 11.3 (broad, N+H) ppm.
1H-NMR (D6-DMSO): S=2.1 (2H), 2.3 (2H), 2.4 (3H), 2.7 (3H), 2.8-3.2 (6H), 3.25-3.8 (7H), 4.1-4.4 (1H), 6.75 (1H), 7.15 (1H), 7.2-7.4 (3H), 7.9 (1H), 8.0 (2H), 8.05 (1H), 8.2 (1H), 10.8 (broad, N+H) and 11.9 (broad, N+H) ppm.
1H NMR (400 MHz, DMSO-d6) δ 8.15 (1H), 8.00 (1H), 7.80 (1H), 7.75 (1H), 7.40 (1H), 7.25 (2H), 7.15 (1H), 7.05 (1H), 6.95 (1H), 3.60 (2H), 3.10 (2H), 2.80 (2H), 2.45 (2H), 2.35 (2H), 2.15 (4H), 1.90 (2H), 1.70 (2H), 1.40 (2H); MS (API-ES, pos) m/z=629 [M+H]
1H-NMR (D6-DMSO): δ=2.1 (2H), 2.25-2.4 (5H), 2.7 (3H), 2.9-3.1 (4H), 3.2 (1H), 3.3-4.0 (13H), 4.3 (1H), 6.7 (1H), 6.8 (1H), 7.1 (2H), 7.2-7.3 (2H), 7.7 (2H), 8.1 (1H), 10.6 (broad, N+H) and 11.6 (broad, N+H) ppm.
1H-NMR (D2O): δ=1.95 (2H), 2.4 (2H), 2.85 (3H), 3.1 (2H), 3.2-3.8 (16H), 4.0 (1H), 6.7 (1H), 6.9 (1H), 7.0 (1H), 7.1 (1H), 7.4 (1H), 7.7-7.9 (3H), 8.2 (1H), 8.3 (1H), and 8.7 (1H) ppm.
1H-NMR (CDCI3): δ=1.25 (3H), 1.55 (2H), 1.7 (2H), 1.9 (2H), 2.2-2.35 (4H), 2.4 (2H), 2.4-2.6 (2H), 2.9 (2H), 3.05 (2H), 3.6 (2H), 3.7 (3H), 3.75 (1H), 3.95 (1H), 6.55 (1H), 6.75 (1H), 6.8 (1H), 7.0 (1H), 7.05 (1H), 7.25 (1H), 7.6 (1H), 7.7 (1H), 7.8 (1H) and 7.9 (1H) ppm.
1H-NMR (CDCI3): δ=1.2 (3H), 1.4-1.7 (4H), 1.75 (2H), 1.9 (2H), 2.2-2.5 (7H), 2.6 (2H), 2.9 (2H), 3.1 (1H), 3.25 (1H), 3.6 (2H), 3.7 (3H), 3.75 (1H), 4.0 (1H), 6.5 (1H), 6.75 (1H), 6.8 (1H), 7.0 (1H), 7.25 (1H), 7.45 (1H), 7.7 (1H), 7.8 (1H) and 7.9 (1H) ppm.
1H-NMR (CDCI3): δ=1.25 (3H), 1.45-1.6 (2H), 1.75 (2H), 1.9 (2H), 2.2-2.3 (4H), 2.4 (2H), 2.4-2.65 (2H), 2.9 (2H), 2.95-3.15 (2H), 3.6 (2H), 3.8 (1H), 4.0 (1H), 6.8 (1H), 6.95 (1H), 7.0 (1H), 7.1 (1H), 7.25-7.35 (2H), 7.65 (1H), 7.7 (1H), 7.85 (1H) and 7.9 (1H) ppm.
1H-NMR (CDCI3): δ=1.25 (3H), 1.55 (2H), 1.75 (2H), 1.9 (2H), 2.2-2.3 (4H), 2.3-2.7 (4H), 2.9 (2H), 3.1 (2H), 3.6 (2H), 3.75 (3H), 3.8 (1H), 4.0 (1H), 6.75 (2H), 6.95 (1H), 7.0 (1H), 7.3 (2H), 7.5 (1H), 7.7 (1H) and 7.9 (1H) ppm.
1H-NMR (CDCI3): δ=1.25 (3H), 1.5-1.65 (2H), 1.7 (2H), 1.9 (2H), 2.2-2.35 (6H), 2.4-2.7 (2H), 2.9 (3H), 3.0 (1H), 3.45-3.6 (2H), 3.8 (1H), 4.0 (1H), 6.75 (2H), 6.9 (1H), 7.0 (1H), 7.2-7.4 (3H), 7.5 (1H), 7.65 (1H), 7.9 (1H), 8.05 (1H), 8.25 (1H) and 8.7 (1H) ppm.
1H-NMR (CDCI3): δ=1.3 (3H), 1.5-1.65 (2H), 1.7 (2H), 1.9 (2H), 2.2-2.4 (9H), 2.4-2.6 (2H), 2.8-3.0 (3H), 3.05 (1H), 3.6 (2H), 3.8 (1H), 4.0 (1H), 6.75 (1H), 6.9 (1H); 7.0 (1H), 7.2-7.4 (2H), 7.65 (2H), 7.65 (1H), 8.0 (1H), 8.15 (1H) and 8.5 (1H) ppm.
1H-NMR (CDCI3): δ=1.4-1.6 (5H), 1.75 (2H), 1.9 (2H), 2.15-2.35 (4H), 2.4-2.5 (4H), 2.9 (2H), 3.1-3.4 (4H), 3.7 (3H), 4.1-4.3 (2H), 6.75-6.95 (6H), 7.05 (1H), 7.25 (1H), 7.6 (1H), 7.75 (1H) and 7.9 (1H) ppm.
1H-NMR (CDCI3): δ=1.4-1.65 (5H), 1.75 (2H), 1.9 (2H), 2.2-2.35 (4H), 2.8-3.1 (4H), 2.9 (2H), 3.15-3.3 (4H), 4.1-4.3 (2H), 6.6 (1H), 6.8-7.0 (2H), 7.0 (1H), 7.1 (1H), 7.2-7.35 (3H), 7.6 (1H), 7.8 (1H) and 7.95 (1H) ppm.
1H-NMR (D6-DMSO): δ=1.2 (3H), 1.9-2.1 (2H), 2.3 (2H), 2.7 (3H), 2.75-3.6 (13H), 3.8-4.0 (2H), 6.95 (2H), 7.2 (1H), 7.25-7.4 (2H), 7.5 (1H), 7.75 (2H), 7.9 (1H), 8.15 (2H), 8.8 (1H), 10.4 (broad, N+H) and 11.1 (broad, N+H) ppm.
1H-NMR (CDCI3): δ=1.4-1.65 (5H), 1.75 (2H), 1.95 (2H), 2.2-2.35 (4H), 2.4-2.55 (4H), 2.9 (2H), 3.15-3.3 (4H), 4.1-4.3 (2H), 6.7 (1H), 6.8-6.95 (2H), 7.0 (1H), 7.2-7.35 (4H), 7.55 (1H), 7.75 (1H) and 8.35 (1H) ppm.
1H-NMR (CDCI3): δ=1.4-1.8 (7H), 1.9 (2H), 2.2-2.35 (4H), 2.4-2.55 (7H), 2.9 (2H), 3.15-3.35 (4H), 4.1-4.3 (2H), 6.8 (1H), 6.85-6.95 (2H), 7.0 (1H), 7.2-7.35 (3H), 7.65 (1H), 7.9 (1H), 8.15 (1H) and 8.50 (1H) ppm.
1H-NMR (CDCI3): δ=1.25 (3H), 1.6 (2H), 1.75 (2H), 2.0 (2H), 2.3 (4H), 2.35 (2H), 2.5 (1H), 2.6 (1H), 2.95 (2H), 3.0-3.15 (2H), 3.55 (2H), 3.75 (1H), 4.0 (1H), 6.7 (1H), 6.75 (1H), 6.95-7.15 (2H), 7.2-7.4 (2H), 7.6 (1H), 7.7 (1H), 7.85 (1H) and 7.9 (1H) ppm.
1H-NMR (CDCI3): δ=1.25 (3H), 1.6-1.9 (6H), 2.05 (2H), 2.3-2.6 (9H), 2.9-3.2 (4H), 3.55 (2H), 3.8 (1H), 4.05 (1H), 6.65 (1H), 6.75 (1H), 6.95-7.1 (2H), 7.25 (1H), 7.65 (1H), 8.0 (1H), 8.15 (1H) and 8.50 (1H) ppm.
1H-NMR (CDCI3): δ=0.85 (3H), 1.0 (3H), 2.1 (1H), 2.3 (2H), 2.5-2.7 (3H), 2.75 (1H), 2.45 and 3.0 (3H), 3.35 (1H), 3.65 and 3.7 (3H), 6.80 (1H), 6.95 (1H), 7.0 (1H), 7.3 (2H), 7.4 (1H), 7.6-7.8 (2H), 8.05 (1H), 8.15 (2H) and 8.75-8.9 (2H) ppm.
1H-NMR (CDCI3): δ=1.25 (3H), 1.40-1.8 (6H), 1.90 (2H), 2.10-2.40 (4H), 2.45 (2H), 2.80 (2H), 2.9 (2H), 3.5 (2H), 3.70 (3H), 3.8 (1H), 4.1 (1H), 6.55 (1H), 6.80 (1H), 6.85-7.0 (2H), 7.25 (1H), 7.40 (1H), 7.60 (2H), 8.00 (1H), 8.05-8.2 (2H) and 8.75-8.9 (2H) ppm.
1H-NMR (CDCI3): δ=1.25 (3H), 1.40-1.8 (6H), 1.90 (2H), 2.10-2.40 (4H), 2.45 (2H), 2.70 (2H), 2.9 (2H), 3.5 (2H), 3.8 (1H), 4.05 (1H), 6.80 (1H), 6.85-7.0 (2H), 7.25 (1H), 7.3-7.5 (2H), 7.5-7.7 (2H), 8.05 (1H), 8.15 (1H), 8.25 (1H) and 8.75 (2H) ppm.
1H-NMR (CDCI3): δ=1.5 (3H), 1.6 (2H), 1.75 (2H), 1.95 (2H), 2.2-2.35 (4H), 2.45 (4H), 2.9 (2H), 3.2 (4H), 4.2 (2H), 6.55 (1H), 6.6 (1H), 6.90 (2H), 7.15 (1H), 7.30 (2H), 7.45 (1H), 7.65 (1H), 8.05 (2H), 8.20 (1H), 8.75 (1H) and 8.80 (1H) ppm.
1H-NMR (CDCI3): δ=1.25 (3H), 1.4-1.9 (6H), 2.0-2.6 (8H), 2.7 (2H), 3.05 (2H), 3.50 (2H), 3.8 (1H), 4.05 (1H), 6.65 (1H), 6.75 (1H), 6.95 (1H), 7.1 (1H), 7.30 (1H), 7.40 (1H), 7.60 (1H), 7.65 (1H), 8.05 (1H), 8.15 (1H), 8.25 (1H) and 8.75 (2H) ppm.
1H-NMR (CDCI3): δ=1.25 (3H), 1.40-1.75 (5H), 1.90 (2H), 2.10-2.30 (5H), 2.45 (2H), 2.60 (2H), 2.9 (2H), 3.45 (2H), 3.70 (1H), 4.05 (1H), 6.75 (1H), 6.95 (1H), 7.20 (1H), 7.30 (1H), 7.40 (1H), 7.60-7.80 (3H), 8.05 (1H), 8.15 (1H), 8.50 (1H), 8.70 (1H) and 8.75 (1H) ppm.
1H NMR (400 MHz, DMSO-d6) δ 8.20 (3H), 8.00 (1H), 7.75 (1H), 7.50 (1H), 7.30 (2H), 7.20 (1H), 3.60 (2H), 3.35 (3H), 3.10 (2H), 2.75 (2H), 2.35 (2H), 2.10 (4H), 1.80 (2H), 1.65 (2H), 1.35 (4H); MS (API-ES, pos) m/z=646 [M+H]
1H-NMR (400 MHz, CDCI3) δ (ppm): 8.74 (1H, d), 8.32 (1H, d), 8.11 (1H, m), 8.00-7.86 (3H, m), 7.56-7.50 (1H, m), 6.94 (1H, t), 6.86 (1H, d), 6.52 (1H, s), 3.73 (3H, s), 3.70 (3H, s), 3.56 (2H, s br.), 3.13 (2H, q br.), 2.91 (2H, d br.), 2.65-1.39 (13H, m br.); MS (API-ES, pos) m/z=637 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.20 (3H), 8.05 (1H), 7.95 (2H), 7.75 (1H), 7.30 (1H), 7.20 (1H), 3.60 (2H), 3.10 (2H), 2.80 (2H), 2.35 (2H), 2.15 (4H), 2.00 (1H), 1.85 (2H), 1.65 (2H), 1.35 (3H); MS (API-ES, pos) m/z=637 [M+H]
MS (ESI, pos) m/z=716 [M+H]
MS (ESI, pos) m/z=680 [M+H]
MS (ESI, pos) m/z=646 [M+H]
MS (ESI, pos) m/z=658 [M+H]
MS (ESI, pos) m/z=660 [M+H]
MS (ESI, pos) m/z=660 [M+H]
MS (ESI, pos) m/z=674 [M+H]
MS (ESI, pos) m/z=696 [M+H]
MS (ESI, pos) m/z=646 [M+H]
1-(benzo[b]thiophene-2-sulfonyl)-5-chloro-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl ester diacetate
MS (ESI, pos) m/z=696 [M+H]
1H-NMR (D6-DMSO): δ=1.4-1.6 (3H), 1.8-2.1 (3H), 2.8-3.6 (15H), 3.7 (1H), 4.1 (1H), 6.6 (1H), 6.95 (1H), 7.2-7.4 (3H), 7.55 (2H), 7.95 (1H), 8.0-8.2 (2H) and 8.5 (1H) ppm.
1H-NMR (CDCI3): δ=1.4 (2H), 1.65 (2H), 1.8-2.0 (5H), 2.05-2.15 (4H), 2.35 (2H), 2.45 (2H), 2.8 (2H), 3.05 (2H), 3.4 (2H), 6.8 (1H), 7.3 (1H), 7.4 (1H), 7.55 (1H), 7.65 (1H), 7.8 (1H), 8.0 (1H), 8.4 (1H), 8.5 (2H) and 8.6 (1H) ppm.
Benzyl-methyl-carbamic acid 5-chloro-3-(2-methoxy-phenyl)-2-oxo-1-(quinoline-8-sulfonyl)-2,3-dihydro-1H-indol-3-yl ester
Benzyl-carbamic acid 5-chloro-1-(2,4-dimethoxy-benzenesulfonyl)-3-(3-methyl-thiophen-2-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl ester
Unless stated otherwise, the following examples bearing amines in the 3-position of the oxindole core can be synthesized according to synthesis Scheme 1 in analogous fashion to Examples 1 to 6.
The amide derivatives of amino acids were acquired from commercial suppliers or synthesized according to standard methods, for example according to the following procedure:
To a solution of (S)—Boc-N-Me-Ala-OH (9.8 mmol, 2.00 g, from Bachem) in DMF (10 mL) were added 1-Hydroxy-1H-benzotriazole (10.8 mmol, 1.46 g) and EDCI (10.8 mmol, 2.08 g). The reaction mixture was stirred for 10 min before a 2M solution of dimethylamine in THF (11.8 mmol, 5.9 mL) was added. After stirring for 18 h at room temperature, water was added and the mixture was extracted several times with ethyl acetate. The combined organic layers were washed with 1N aqueous hydrochloric acid, aqueous sodium bicarbonate solution and water. After drying over magnesium sulfate, the volatiles were removed in vacuo. Yield: 1.86 g of a colorless oil (82%). The Boc-protected coupling product was dissolved in MeOH (19 mL) and treated with a 4N solution of HCl in dioxane (32.3 mmol, 8.1 mL). After stirring for 18 h at room temperature, the reaction mixture was evaporated to dryness to leave 1.41 g of a white solid (quantitative yield).
(S)-Pyrrolidine-2-carboxylic acid dimethylamide hydrochloride, (S)-Pyrrolidine-2-carboxylic acid methylamide hydrochloride, (S)-Piperidine-2-carboxylic acid dimethylamide hydrochloride, (S)-Azetidine-2-carboxylic acid dimethylamide hydrochloride, (S)-2,5-Dihydro-1H-pyrrole-2-carboxylic acid dimethylamide hydrochloride, (2S,4R)-4-Fluoro-pyrrolidine-2-carboxylic acid dimethylamide hydrochloride, (2S,4S)-4-Hydroxy-pyrrolidine-2-carboxylic acid dimethylamide hydrochloride, (2S,4R)-4-Hydroxy-piperidine-2-carboxylic acid dimethylamide hydrochloride, N,N-Dimethyl-2-methylamino-acetamide hydrochloride, 2-Amino-N,N-dimethyl-acetamide hydrochloride, Pyrrolidine-3-carboxylic acid dimethylamide hydrochloride, (S)-2-Amino-N,N-dimethyl-propionamide hydrochloride, (S)-2-Amino-N,N-dimethyl-butyramide hydrochloride were prepared in analogous fashion.
[α]D20° C. (c=0.1, CHCI3): −197;
1H NMR (400 MHz, DMSO-d6) δ 8.10 (1H), 7.95 (2H), 7.85 (1H), 7.50 (1H), 7.15 (1H), 6.90 (1H), 6.75 (2H), 4.00 (1H), 3.85 (3H), 3.75 (3H), 3.25 (3H), 2.75 (3H), 2.35 (3H), 0.90 (3H); MS (API-ES, pos) m/z=603 [M+H]
[α]D20° C. (c=0.1, CHCI3): −152;
1H NMR (400 MHz, DMSO-d6) δ 8.20 (1H), 8.10 (1H), 7.95 (1H), 7.85 (1H), 7.50 (1H), 7.10 (1H), 7.00 (1H), 6.80 (1H), 6.75 (1H), 3.90 (3H), 3.80 (3H), 3.40 (2H), 3.25 (3H), 2.75 (3H), 2.65 (3H), 0.90 (3H); MS (API-ES, pos) m/z=589 [M+H]
1H-NMR (D6-DMSO): S=1.65 (1H), 1.9 (3H), 2.0 (1H), 2.45 (3H), 2.6 (3H), 2.65 (1H), 3.3 (1H), 3.5 (3H), 3.9 (3H), 4.3 (1H), 4.7 (1H), 5.6 (1H), 6.7 (1H), 6.75 (1H), 7.1 (1H), 7.25 (1H), 7.45 (1H), 7.55 (1H), 7.75 (1H), 7.95 (1H) and 8.15 (1H) ppm.
1H NMR (400 MHz, DMSO-d6) δ 8.45 (1H), 8.25 (1H), 8.10 (1H), 7.70-7.90 (4H), 7.45 (1H), 7.10 (1H), 7.05 (1H), 5.00 (1H), 4.45 (1H), 4.27 (1H), 3.25 (1H), 2.95 (3H), 2.70 (1H), 2.40 (3H), 2.05 (1H), 1.70 (1H); MS (API-ES, pos) m/z=571 [M+H]
A solution of Example 5 (0.16 mmol, 100 mg) and sodium iodide (0.32 mmol, 109 mg) in acetic acid (1 mL) was heated overnight at 40° C. The reaction mixture was diluted with ethyl acetate and washed with aqueous sodium dithionite solution, water and brine. The organic layer was dried over magnesium sulfate and concentrated in vacuo. Chromatographic purification over silica gel (gradient from 4% to 12% MeOH in dichloromethane) yielded 59 mg (60%) of a white crystalline solid.
1H NMR (400 MHz, DMSO-d6) δ 11.55 (1H), 7.90 (2H), 7.70 (1H), 7.40 (1H), 7.30 (1H), 7.00 (1H), 6.70 (1H), 6.65 (1H), 6.70 (1H), 4.90 (1H), 4.60 (1H), 4.30 (1H), 3.85 (3H), 3.55 (3H), 2.90 (1H), 2.60 (3H), 2.55 (3H), 2.25 (1H), 1.60 (1H); MS (API-ES, pos) m/z=617 [M+H]
[α]D20° C. (c=0.1, CHCI3): −285;
1H NMR (400 MHz, DMSO-d6) δ 8.20 (1H), 8.10 (1H), 8.00 (1H), 7.80 (1H), 7.37 (1H), 6.90-7.15 (3H), 6.77 (1H), 6.70 (1H), 4.90 (1H), 4.55 (1H), 4.45 (1H), 3.85 (3H), 3.70 (3H), 3.40 (3H), 2.85 (1H), 2.60 (3H), 2.35 (3H), 2.15 (1H), 1.30-1.70 (2H); MS (API-ES, pos) m/z=597 [M+H]
(S)-1-[1-(2,4-Dimethoxy-benzenesulfonyl)-3-(2-methoxy-pyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]pyrrolidine-2-carboxylic acid dimethylamide, levorotatory diastereomer
[α]D20° C. (c=0.1, CHCI3): −210;
1H NMR (400 MHz, DMSO-d6) δ 8.10 (2H), 7.95 (1H), 7.80 (1H), 7.40 (1H), 7.15 (1H), 7.00 (2H), 6.77 (2H), 4.50 (1H), 3.87 (3H), 3.65 (3H), 3.50 (3H), 2.70 (3H), 2.40 (3H), 2.20 (1H), 1.75 (1H), 1.40 (3H); MS (API-ES, pos) m/z=581 [M+H]
[α]D20° C. (c=0.1, CHCI3): −242;
1H NMR (400 MHz, DMSO-d6) δ 8.10 (2H), 7.95 (1H), 7.80 (1H), 7.50 (1H), 7.05 (2H), 6.80 (2H), 4.50 (1H), 3.87 (3H), 3.70 (3H), 3.50 (3H), 2.75 (1H), 2.70 (3H), 2.45 (3H), 2.20 (1H), 1.75 (1H), 1.40 (3H); MS (API-ES, pos) m/z=615 [M+H]
[α]D20° C. (c=0.1, CHCI3): −200;
1H-NMR (400 MHz, DMSO-d6) δ 8.15 (1H, s br.), 8.07 (1H, m), 7.97 (1H, d), 7.67 (1H, d), 7.17 (1H, d), 7.01 (1H, t), 6.86-6.66 (3H, m), 4.87 (1H, s), 4.56 (1H, d), 4.34 (1H, sext.), 3.86 (3H, s), 3.70 (3H, s), 2.59 (3H, s br.), 2.35 (3H, s), 2.21 (3H, s), 1.60 (1H, m); MS (API-ES, pos) m/z=611 [M+H]
1H-NMR (400 MHz, CDCI3) δ 8.27 (1H, d), 8.22 (2H, s br.), 8.03 (1H, m), 7.79 (1H, d), 7.68 (1H, t), 7.60 (2H, m), 7.10 (1H, d), 6.90 (1H, t), 6.77 (1H, s), 4.74 (1H, s br.), 4.55 (1H, m), 3.22 (3H, s br.), 2.73 (3H, s br.), 2.42 (3H, s br.), 2.20 (3H, s), 1.94 (1H, m), 1.84 (1H, s br.); MS (API-ES, pos) m/z=551 [M+H]
[α]D20° C. (c=0.1, CHCI3): −137;
1H-NMR (500 MHz, DMSO-d6) δ 8.17 (1H, d), 8.06 (1H, d), 7.99 (1H, d), 7.70 (1H, d), 7.00 (1H, t), 6.94 (1H, d), 6.72 (1H, d), 6.70 (1H, s), 6.47 (1H, s), 4.70 (1H, s br.), 4.58 (1H, d), 4.36 (1H, s br.), 3.86 (3H, s), 3.72 (3H, s), 3.67 (3H, s), 3.42 (3H, s), 2.94 (1H, s br.), 2.60 (3H, m), 2.38 (3H, m), 2.20 (1H, s br.), 1.66-1.47 (2H, m); MS (API-ES, pos) m/z=627 [M+H]
[α]D20° C. (c=0.1, CHCI3): −192;
1H-NMR (500 MHz, DMSO-d6) δ 8.37 (1H, m), 8.17 (2H, d), 8.02 (1H, m), 7.76 (1H, t), 7.68 (2H, t), 7.62 (1H, d), 7.02 (1H, t), 6.90 (1H, d), 6.44 (1H, s), 4.80 (1H, s br.), 4.47 (1H, m), 4.30 (1H, s br.), 3.64 (3H, s), 3.04 (3H, s), 2.60 (1H, m br.), 2.44 (6H, s), 1.96 (1H, s br.), 1.70 (1H, m); MS (API-ES, pos) m/z=567 [M+H]
A 1.7 M solution of tert-butyllithium in pentane (35 ml, 60 mmol) was added to THF (100 ml) at −78° C. 2-Bromomesitylene (4.6 ml, 30 mmol) was added dropwise and the mixture stirred at −78° C. for 1 h. 2-Methoxypyridine (3.2 ml, 30 mmol) was added at −78° C. and then the mixture was stirred at 0° C. for 1.5 h. The ice-cold solution of the lithiated 2-methoxypyridine was transferred (via a transfer needle) into an ice-cold suspension of 5-iodoisatin (4.1 g, 15 mmol) in THF (150 ml). The reaction mixture was allowed to warm to room temperature and then saturated ammonium chloride solution was added. The mixture was extracted three times with ethyl acetate, and the collected extracts were washed with saturated brine. The organic phase was dried over magnesium sulfate, filtered and concentrated under reduced pressure. Purification by crystallization from dichloromethane yielded 2.9 g of the intermediate.
MS (API-ES, pos) m/z=383 [M+H]
The chlorination/amination sequence was performed as described for Examples 5 and 6 (Steps B and C). The two diastereomers were separated by flash chromatography over silica gel (gradient from 4% to 10% MeOH in dichloromethane). The major diastereomer was the later eluting one and led to the required levorotatory product.
MS (API-ES, pos) m/z=523 [M+H]
The sulfonylation was performed as described for Example 5 (Step D).
MS (API-ES, pos) m/z=723 [M+H]
A solution of Example 232C (0.69 mmol, 500 mg), zinc zyanide (0.69 mmol, 81 mg) and palladium(0)-tetrakis-triphenylphosphine (15 mg) in DMF (3 mL) was heated at 75° C. for 24 h. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with water and brine. After drying over magnesium sulfate, the volatiles were evaporated in vacuo. The remaining oil was triturated with dichloromethane and the white solid was collected by filtration. The crude product was purified by flash chromatography over silica gel (gradient from 4% to 10% MeOH in dichloromethane). Yield: 315 mg of the desired product as a white solid (73%).
1H NMR (400 MHz, DMSO-d6) δ 8.32 (1H), 8.08 (1H), 8.00 (1H), 7.92 (1H), 7.86 (1H), 7.54 (1H), 7.05 (1H), 6.72-6.80 (2H), 4.98 (1H), 4.55 (1H), 4.32 (1H), 3.88 (3H), 3.73 (3H), 3.03 (1H), 2.45 (3H), 1.55-1.80 (2H); MS (API-ES, pos) m/z=622 [Mi-H]
MS (API-ES, pos) m/z=606 [M+H]
A 1.7 M solution of tert-butyllithium in pentane (57.8 mL) was added to THF (200 ml) at −78° C. 2-Bromomesitylene (3.6 mL) was added dropwise, keeping the temperature below −60° C., and the mixture stirred at −78° C. for 1 h. 3-Methoxypyridine (3.6 mL) was added dropwise at −78° C. and then the mixture was allowed to warm to −5° C. over 2 h. The reaction mixture was re-cooled to −78° C. and a slurry of 5-chloroisatin (3.26 g) in THF (100 mL) was added portionwise keeping the temperature below −60° C. The reaction mixture was stirred at −78° C. for 1 h. The cooling bath was removed and the reaction mixture was stirred for 30 min. The reaction mixture was quenched with 10% aqueous ammonium chloride solution and extracted several times with ethyl acetate. The combined organic layers were washed with water, dried over magnesium sulfate and evaporated to low volume. Upon standing, 0.73 g of a pale yellow solid separated which was filtered off, washed with ethyl acetate and dried in vacuo.
The subsequent steps were performed in analogous fashion to Examples 5 and 6.
[α]D20° C. (c=0.1, CHCI3): −212;
1H NMR (400 MHz, DMSO-d6) δ 8.25 (2H), 8.00 (1H), 7.85 (1H), 7.75 (1H), 7.45 (1H), 7.00
(1H), 6.75 (2H), 4.95 (1H), 4.55 (1H), 4.35 (1H), 3.85 (3H), 3.75 (3H), 3.40 (3H), 3.00 (1H), 2.55 (3H), 2.40 (3H), 2.30 (1H), 1.65 (1H); MS (API-ES, pos) m/z=631 [M+H]
[α]D20° C. (c=0.1, CHCI3): −23;
1H-NMR (400 MHz, CDCI3) δ 8.13 (1H, d), 8.06 (1H, d), 7.99 (1H, d), 7.88 (1H, d), 7.70 (1H, t), 7.09 (1H, m), 6.61 (1H, dd), 6.47 (1H, s), 4.35 (1H, s br.), 3.98 (3H, m), 3.89 (3H, s), 3.54 (dd, 1H), 3.46 (3H, s), 2.74 (3H, s), 2.67 (1H, d), 2.55 (3H, s), 2.11 (1H, m), 1.91 (1H, m); MS (API-ES, pos) m/z=601 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.95 (1H), 8.10 (2H), 7.70 (1H), 7.40 (1H), 7.20 (3H), 5.05 (1H), 4.40° (1H), 4.25 (1H), 3.85 (6H), 3.25 (1H), 3.15 (3H), 2.75 (1H), 2.35 (3H), 2.00 (1H), 1.65 (1H); MS (API-ES, pos) m/z=632 [M+H]
[α]D20° C. (c=0.1, CHCI3): −195;
1H NMR (400 MHz, DMSO-d6) δ 8.20 (1H), 8.05 (1H), 7.95 (1H), 7.85 (1H), 7.50 (1H), 7.15 (1H), 6.85 (1H), 6.75 (2H), 3.70-3.95 (8H), 2.95 (3H), 2.65 (3H), 2.20 (3H), 1.85 (1H), 1.30-1.70 (5H); MS (API-ES, pos) m/z=629 [M+H]
To a stirred solution of 2,6-dimethoxypyridine (50 mmol, 6.61 mL) in THF (100 mL) was added slowly a 1.6 M solution of n-butyllithium in hexanes (55 mmol, 34.4 mL) at −78° C. The mixture was allowed to warm slowly to 10° C. and kept at this temperature for 30 min. The reaction mixture was re-cooled to −78° C. and a slurry of 5-chloroisatin (20 mmol, 3.63 g) in THF (150 mL) was added portionwise, keeping the temperature below −60° C. The reaction was allowed to come to room temperature. The mixture was quenched with 10% aqueous ammonium chloride solution and extracted several times with ethyl acetate. The combined organic layers were washed with water, dried over magnesium sulfate and evaporated in vacuo. Recrystallization from ethyl acetate yielded 4.56 g (71%) of the desired intermediate as a white crystalline solid (71%).
MS (API-ES, pos) m/z=321 [M+H]
The subsequent steps were performed as described for Example 5 and Example 6.
1H NMR (400 MHz, DMSO-d6) δ 8.05 (1H), 8.00 (1H), 7.80 (1H), 7.45 (1H), 7.00 (1H), 6.75 (2H), 6.40 (1H), 4.90 (1H), 4.55 (1H), 4.30 (1H), 3.85 (3H), 3.80 (3H), 3.70 (3H), 3.40 (3H), 2.90 (1H), 2.55 (3H), 2.45 (3H), 2.20 (1H), 1.60 (2H); MS (API-ES, pos) m/z=661 [M+H]
Example 239 was synthesized in analogy to Example 5, substituting 2-methoxypyridine with 2-ethoxypyridine in Step A.
[α]D20° C. (c=0.1, CHCI3): −228;
1H NMR (400 MHz, DMSO-d6) δ 8.20 (1H), 8.10 (1H), 8.00 (1H), 7.80 (1H), 7.45 (1H), 7.00 (2H), 6.75 (2H), 4.95 (1H), 4.55 (1H), 4.30 (1H), 3.95 (2H), 3.85 (3H), 3.70 (3H), 2.90 (1H), 2.55 (3H), 2.45 (3H), 2.25 (1H), 1.60 (1H), 0.80 (3H); MS (API-ES, pos) m/z=645 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.40 (1H), 8.15 (2H), 8.05 (1H), 7.70 (1H), 7.40 (1H), 7.20 (2H), 7.10 (1H), 7.00 (1H), 5.00 (1H), 4.45 (1H), 4.30 (1H), 3.85 (3H), 3.20 (1H), 3.05 (3H), 2.65 (1H), 2.40 (3H), 2.05 (1H), 1.65 (1H); MS (API-ES, pos) m/z=601 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.25 (1H), 8.10 (2H), 7.75 (2H), 7.45 (1H), 7.30 (1H), 7.20 (1H), 7.05 (2H), 4.95 (1H), 4.55 (1H), 4.35 (1H), 3.75 (3H), 3.00 (1H), 2.55 (3H), 2.45 (3H), 2.25 (1H), 1.65 (2H); MS (API-ES, pos) m/z=601 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.50 (1H), 8.15 (2H), 8.10 (1H), 7.85 (2H), 7.50 (1H), 7.20 (2H), 7.10 (1H), 5.05 (1H), 4.45 (1H), 4.30 (1H), 3.85 (3H), 3.20 (1H), 3.05 (3H), 2.70 (1H), 2.35 (3H), 2.05 (1H), 1.65 (1H); MS (API-ES, pos) m/z=592 [M+H]
[α]D20° C. (c=0.1, CHCI3): −9;
1H-NMR (400 MHz, CDCI3) δ 8.17 (1H, d), 8.12 (2H, dd), 7.72 (1H, d), 7.63 (1H, d), 7.16 (1H, s), 6.58 (1H, dd), 6.51 (1H, s), 5.48 (1H, s br.), 4.71 (1H, t), 4.26 (1H, s), 3.83 (6H, d), 3.59 (3H, s), 3.32 (1H, dd), 3.10 (1H, d), 2.88 (3H, s), 2.56 (3H, s), 2.22 (1H, m sym.), 1.74 (1H, m sym.)
1H NMR (400 MHz, DMSO-d6) δ 8.70 (1H), 8.00 (1H), 7.65 (1H), 6.95 (1H), 6.75 (2H), 6.60 (1H), 4.90 (1H), 4.60 (1H), 4.30 (1H), 3.85 (6H), 3.70 (6H), 3.40 (3H), 3.00 (1H), 2.55 (3H), 2.45 (3H), 2.25 (1H), 1.65 (1H); MS (API-ES, pos) m/z=658 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.25 (1H), 8.10 (1H), 8.00 (1H), 7.90 (1H), 7.45 (1H), 7.05 (1H), 7.00 (1H), 6.80 (1H), 6.75 (1H), 4.95 (1H), 4.55 (1H), 4.35 (1H), 3.85 (3H), 3.70 (3H), 3.40 (3H), 2.90 (1H), 2.60 (3H), 2.40 (3H), 2.20 (1H), 1.65 (1H); MS (API-ES, pos) m/z=681 [M+H]
[α]D20° C. (c=0.1, CHCI3): −207;
1H NMR (400 MHz, DMSO-d6) δ 8.20 (1H), 8.10 (1H), 8.00 (1H), 7.75 (1H), 7.45 (1H), 7.10 (2H), 6.75 (2H), 5.25 (1H), 4.60 (1H), 3.85 (3H), 3.75 (3H), 3.40 (1H), 3.25 (3H), 2.85 (1H), 2.45 (6H), 2.30 (1H), 1.85 (1H); MS (API-ES, pos) m/z=633 [M+H]
MS (API-ES, pos) m/z=613 [M+H]
MS (ESI, pos) m/z=626 [M+H]
Sodium acetoxyborohydride (0.36 mmol, 76.27 mg) was added to a solution of Example 61 (0.24 mmol, 0.15 g), acetic acid (0.24 mmol, 14.4 mg) and aq. formaldehyde (37%, 0.26 mmol, 21.42 mg). The mixture was stirred at RT for 12 h and evaporated in vacuo. The residue was solved in H2O and extracted with ethyl acetate. The organic phase was dried, filtrated and evaporated. The crude product was then purified on a column of silicagel eluted with 5% MeOH in CH2Cl2 to afford 100 mg of the required product.
[α]D20° C. (c=0.1, CHCI3): −112;
MS (API-ES, pos) m/z=639 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.65 (1H), 8.20 (1H), 8.00 (1H), 7.80 (1H), 7.65 (1H), 7.45 (1H), 7.30 (1H), 7.00 (1H), 6.95 (1H), 6.85 (1H), 4.95 (1H), 4.50 (1H), 4.30 (1H), 3.10 (3H), 2.40 (3H), 2.00 (1H), 1.65 (1H); MS (API-ES, pos) m/z=585 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.20 (1H), 8.10 (1H), 8.00 (1H), 7.80 (1H), 7.65 (1H), 7.40 (1H), 7.30 (1H), 7.00 (1H), 6.95 (1H), 6.85 (1H), 4.90 (1H), 4.50 (1H), 4.30 (1H), 3.15 (3H), 2.55 (3H), 2.40 (4H), 1.60 (1H); MS (API-ES, pos) m/z=585 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.15 (1H), 8.10 (1H), 8.00 (1H), 7.70 (1H), 7.30 (2H), 7.20 (1H), 7.00 (1H), 6.80 (2H), 4.95 (1H), 4.50 (1H), 4.30 (1H), 2.95 (4H), 2.45 (3H), 2.00 (1H), 1.70 (1H); MS (API-ES, pos) m/z=560 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.10 (1H), 8.05 (2H), 7.85 (1H), 7.50 (1H), 7.00 (2H), 6.80 (2H), 4.80 (1H), 3.90 (3H), 3.75 (3H), 3.50 (3H), 2.80 (1H), 2.65 (4H), 2.35 (4H), 1.60 (1H); MS (API-ES, pos) m/z=601 [M+H]
[α]D20° C. (c=0.1, CHCI3): −149;
1H NMR (400 MHz, DMSO-d6) δ 8.05 (1H), 7.85 (1H), 7.75 (1H), 7.40 (1H), 7.30 (1H), 7.15 (1H), 7.00 (1H), 6.90 (2H), 4.95 (1H), 4.55 (1H), 4.35 (1H), 3.85 (3H), 3.25 (3H), 2.35 (4H), 1.65 (1H); MS (API-ES, pos) m/z=606 [M+H]
[α]D20° C. (c=0.1, CHCI3): −110;
1H NMR (400 MHz, DMSO-d6) δ 8.45 (1H), 8.17 (1H), 8.07 (2H), 7.70 (1H), 7.43 (1H), 7.30 (1H), 7.03-7.15 (2H), 5.03 (1H), 4.45 (1H); 4.30 (1H), 3.25, 3.05 (3H), 2.70 (1H), 2.40 (3H), 2.05 (1H), 1.70 (1H); MS (API-ES, pos) m/z=577 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.85 (1H), 8.40 (1H), 8.00 (1H), 7.75 (1H), 7.45 (1H), 7.05 (1H), 6.95 (1H), 6.75 (2H), 4.95 (1H), 4.60 (1H), 4.35 (1H), 3.85 (3H), 3.75 (3H), 3.35 (3H), 3.00 (1H), 2.55 (3H), 2.45 (3H), 1.60 (2H); MS (API-ES, pos) m/z=552 [M+H]
[α]D20° C. (c=0.1, CHCI3): −166;
1H-NMR (500 MHz, DMSO-d6) δ 8.79 (1H, d), 8.42 (2H, m), 8.28 (1H, t), 8.05 (1H, d), 7.77 (1H, m), 7.68 (1H, d), 7.14 (1H, d), 7.04 (1H, t), 6.77 (1H, s), 4.80 (1H, s), 4.44 (1H, m), 4.33 (1H, m), 3.25 (3H, s), 3.15 (3H, s), 2.58 (1H, s br.), 2.43 (3H, s), 2.39 (3H, s), 2.19 (3H, s), 1.85 (1H, s br.), 1.66 (1H, m); MS (API-ES, pos) m/z=552 [M+H]
[α]D20° C. (c=0.1, CHCI3): −157;
1H-NMR (400 MHz, CDCI3) δ 8.25 (1H, s br.), 8.03 (2H, m), 7.72 (2H, m), 7.18 (1H, t), 7.09 (1H, d), 6.91 (1H, t), 6.81 (1H, s), 4.76 (1H, s br.), 4.57 (1H, m), 3.35 (3H, s br.), 2.72 (3H, br.), 2.45 (3H, s), 2.22 (3H, s), 1.96 (2H, m); MS (API-ES, pos) m/z=557 [M+H]
[α]D20° C. (c=0.1, CHCI3): −209;
1H-NMR (400 MHz, CDCI3) δ 8.54 (1H, s), 8.30 (1H, d), 8.20 (1H, s br.), 8.03 (1H, m), 7.80 (2H, m), 7.08 (1H, d), 6.90 (1H, t), 6.83 (1H, s), 4.74 (1H, s br.), 4.58 (1H, quint.), 3.58 (3H, br.), 2.72 (3H, s br.), 2.44 (3H, s), 2.41 (3H, s), 2.21 (3H, s), 1.88 (1H, m), 1.68 (4H, s); MS (API-ES, pos) m/z=566 [M+H]
[α]D20° C. (c=0.1, CHCI3): −105;
1H-NMR (400 MHz, DMSO-d6) δ 8.81 (1H, d), 8.31 (1H, d), 8.22 (1H, t), 8.05 (1H, d), 7.82 (1H, m), 6.94 (1H, d), 6.48 (1H, s), 4.96 (1H, s br.), 4.47 (1H, s br.), 4.31 (1H, s br.), 3.66 (3H, s), 3.17 (3H, m), 2.38 (3H, s), 1.63 (1H, m); MS (API-ES, pos) m/z=568 [M+H]
[α]D20° C. (c=0.1, CHCI3): −175;
1H-NMR (400 MHz, DMSO-d6) δ 8.41 (1H, s br.), 8.15 (1H, d), 8.04 (2H, m), 7.60 (1H, d), 7.30 (1H, t), 7.07 (1H, t), 6.92 (1H, d), 6.47 (1H, s), 4.99 (1H, s br.), 4.47 (1H, s br.), 4.31 (1H, s br.), 3.65 (3H, s), 3.02 (3H, s), 2.41 (6H, s), 2.00 (1H, m br.), 1.69 (1H, m); MS (API-ES, pos) m/z=573 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.50 (1H), 8.20 (1H), 8.15 (1H), 8.10 (1H), 7.85 (2H), 7.55 (1H), 7.35 (1H), 7.10 (1H), 5.05 (1H), 4.50 (1H), 4.30 (1H), 3.30 (1H), 3.05 (3H), 2.75 (1H), 2.35 (3H), 2.05 (1H), 1.70 (1H); MS (API-ES, pos) m/z=568 [M+H]
[α]D20° C. (c=0.1, CHCI3): −242;
1H NMR (400 MHz, DMSO-d6) δ 8.20 (1H), 8.10 (2H), 8.05 (1H), 7.75 (1H), 7.45 (1H), 7.35 (1H), 7.10 (2H), 4.40 (1H), 3.10 (3H), 3.05 (1H), 2.00 (1H), 1.60-1.90 (2H); MS (API-ES, pos) m/z=561 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.30 (1H), 8.20 (1H), 8.10 (1H), 7.70 (1H), 7.40 (1H), 7.30 (1H), 7.05 (1H), 6.45 (1H), 5.00 (1H), 4.45 (1H), 4.30 (1H), 3.80 (3H), 3.25 (1H), 3.05 (3H), 2.70 (1H), 2.40 (3H), 2.00 (1H), 1.65 (1H); MS (API-ES, pos) m/z=607 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.95 (1H), 8.20 (1H), 8.10 (1H), 7.70 (1H), 7.45 (1H), 7.30 (1H), 7.25 (1H), 5.05 (1H), 4.45 (1H), 4.25 (1H), 3.90 (3H), 3.15 (3H), 2.80 (1H), 2.35 (3H), 2.05 (1H), 1.65 (1H); MS (API-ES, pos) m/z=608 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.90 (1H), 8.65 (1H), 8.20 (1H), 8.05 (1H), 7.75 (1H), 7.45 (1H), 7.25 (1H), 5.05 (1H), 4.40 (1H), 4.25 (1H), 3.90 (3H), 3.25 (3H), 2.70 (1H), 2.45 (3H), 2.35 (3H), 2.00 (1H), 1.65 (1H); MS (API-ES, pos) m/z=617 [M+H]
[α]D20° C. (c=0.1, CHCI3): −11;
1H-NMR (400 MHz, CDCI3) δ 8.14 (3H, m), 7.73 (1H, m), 7.66 (2H, s), 7.19 (1H, t), 7.12 (1H, s), 5.54 (1H, s br.), 4.58 (1H, t), 4.25 (1H, s), 3.40 (3H, s), 3.29 (1H, dd), 3.17 (1H, d), 2.80 (3H, s), 2.52 (3H, s), 2.27 (1H, m sym.), 1.70 (1H, m sym.); MS (API-ES, pos) m/z=671 [M+H]
[α]D20° C. (c=0.1, CHCI3): −8;
1H-NMR (400 MHz, CDCI3) δ 8.55 (1H, s), 8.38 (1H, d), 8.12 (2H, m), 7.80 (2H, t), 7.65 (1H, d), 7.15 (1H, s), 4.56 (1H, t), 4.24 (1H, s), 3.52 (3H, s), 3.30 (1H, dd), 3.12 (1H, d), 2.77 (3H, s), 2.47 (6H, d), 2.26 (1H, m sym.), 1.71 (1H, m sym.); MS (API-ES, pos) m/z=679 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.35 (1H), 8.10 (2H), 7.80 (1H), 7.45 (1H), 7.20 (1H), 7.05 (1H), 7.00 (1H), 5.00 (1H), 4.50 (1H), 4.35 (1H), 3.90 (1H), 3.25 (3H), 3.15 (1H), 2.45 (3H), 1.85 (1H), 1.65 (1H); MS (API-ES, pos) m/z=607 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.35 (1H), 8.10 (1H), 7.85 (1H), 7.40 (1H), 7.20 (1H), 7.05 (1H), 6.95 (1H), 5.00 (1H), 4.50 (1H), 4.35 (1H), 3.90 (3H), 3.25 (3H), 3.15 (1H), 2.40 (3H), 1.85 (1H), 1.70 (1H); MS (API-ES, pos) m/z=657 [M+H]
MS (API-ES, pos) m/z=653 [M+H]
1H NMR (400 MHz, DMSO-d6) δ 8.85 (1H), 8.75 (1H), 8.60 (1H), 8.45 (1H), 8.30 (1H), 8.20 (1H), 8.05 (1H), 7.90 (1H), 7.70 (1H), 7.50 (1H), 7.00 (2H), 4.80 (1H), 4.55 (1H), 4.30 (1H), 3.05 (1H), 2.67 (3H), 1.55-1.90 (2H); MS (API-ES, pos) m/z=622 [M+H]
[α]D20° C. (c=0.1, CHCI3): −178;
1H NMR (400 MHz, DMSO-d6) δ 8.65 (1H), 8.40 (1H), 8.25 (1H), 8.10 (1H), 8.00 (1H), 7.80 (1H), 7.45 (1H), 7.05 (2H), 5.00 (1H), 4.45 (1H), 4.30 (1H), 3.20 (3H), 2.65 (1H), 2.45 (3H), 2.40 (3H), 2.38, 2.00 (1H), 1.65 (1H); MS (API-ES, pos) m/z=586 [M+H]
In the following Table 2 characteristic mass-spectroscopic data are shown for selected examples.
This is a divisional of U.S. patent application Ser. No. 10/574,211, filed on Jan. 22, 2007, which is the U.S. National Stage of International Patent Application No. PCT/EP2004/010940, filed on Sep. 30, 2004, which is a continuation-in-part of U.S. patent application Ser. No. 10/675,300, filed on Sep. 30, 2003, the contents of all of which are hereby incorporated by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 5594023 | Wagnon et al. | Jan 1997 | A |
| 6090818 | Foulon et al. | Jul 2000 | A |
| 6596732 | Serradeil-Le Gal et al. | Jul 2003 | B2 |
| 6624164 | Schoentjes et al. | Sep 2003 | B2 |
| 6864277 | Roux et al. | Mar 2005 | B2 |
| 7119086 | Di Malta et al. | Oct 2006 | B2 |
| 7902379 | Lubisch et al. | Mar 2011 | B2 |
| 20030114683 | Roux et al. | Jun 2003 | A1 |
| 20050070718 | Lubisch et al. | Mar 2005 | A1 |
| 20070021607 | Lubisch et al. | Jan 2007 | A1 |
| 20080318923 | Habuchi et al. | Dec 2008 | A1 |
| 20090005397 | Lubisch et al. | Jan 2009 | A1 |
| 20090163492 | Oost et al. | Jun 2009 | A1 |
| 20090215790 | Lubisch et al. | Aug 2009 | A1 |
| Number | Date | Country |
|---|---|---|
| 2107348 | Jul 1993 | CA |
| 9315051 | Aug 1993 | WO |
| 9518105 | Jul 1995 | WO |
| 9825901 | Jun 1998 | WO |
| 0155130 | Aug 2001 | WO |
| 0155134 | Aug 2001 | WO |
| 0164668 | Sep 2001 | WO |
| 0187295 | Dec 2001 | WO |
| 03008407 | Jan 2003 | WO |
| 2005030755 | Apr 2005 | WO |
| 2006005609 | Jan 2006 | WO |
| 2006080574 | Aug 2006 | WO |
| 2006100081 | Sep 2006 | WO |
| 2006100082 | Sep 2006 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20110071156 A1 | Mar 2011 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 10574211 | US | |
| Child | 12839612 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 10675300 | Sep 2003 | US |
| Child | 10574211 | US |
